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Atropine Sulfate (AS) auto-injector (AtroPen®) is being used as an effective and safe
antidote for the treatment of organophosphate (OP) pesticides or nerve gas poisoning. The
use of AtroPen® is associated with several drawbacks including: bulky size, availability,
affordability, invasiveness, and administration errors. Previously, AS fast disintegrating
sublingual tablets (FDSTs) were developed and the feasibility of AS sublingual
permeability were demonstrated. However, AS permeability was delayed due to the
negative impact of higher doses of AS on FDST’s physical characteristics. Therefore, the
aim in this research project was to optimize the previously developed AS FDSTs. It was
hypothesized that optimizing the tablet’s filler grade will improve the tablet physical
characteristics along with incorporating a pH modifier and penetration enhancers will
significantly enhance AS sublingual permeability.
Ten batches of AS FDSTs containing AS 8 mg were manufactured using a highly
compressible filler grade of microcrystalline cellulose, MCC UF-702. AS FDSTs with and
without a pH modifier (Na Bicarb 2%), or penetration enhancers (sodium dodecyl sulfate
(SDS 0.5% or 1%), palmitoyl carnitine chloride (PCC 16%), or sodium glycocholate (Na
Gly 15% or 20%)) were manufactured and evaluated.
Several US Pharmacopeia (USP) and non-USP physical tests were performed to
evaluate AS FDSTs’ characteristics. AS permeability from the ten AS FDST formulations
were evaluated using Franz cells through excised porcine sublingual membranes. Results
were statistically compared and deemed significant if p< 0.05.
All manufactured AS FDSTs passed the quality control tests. MCC UF-702 grade
resulted in better powder flowability, higher breaking force, faster disintegration, faster
dissolution rate, and higher water uptake. AS sublingual permeability was linear, indicating
for a passive transport. Transcellular enhancers had significantly higher AS permeability
enhancement in comparison to paracellular enhancer. Incorporating Na Bicarb 2% along
with SDS 1% into AS FDSTs resulted in the highest enhancement in AS cumulative

sublingual permeation (AUC0-90 min), influx, and permeability. These optimized novel AS
FDSTs has the potential to deliver therapeutic AS concentrations to the systemic
circulation and achieve rapid onset of action for the first-aid treatment of OP toxicity.
Further pharmacokinetics studies are recommended to determine the bioequivalence
sublingual AS dose to AtroPen®.
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Introduction

Research Rationale

Organophosphate (OP) poisoning is reported by the World Health Organization
(WHO) to cause 300,000 deaths annually (Chowdhary, Bhattacharyya, & Banerjee, 2014)
and 3,000,000 poisoning cases per year (Robb & Baker., 2019). About 60% of the globally
reported cases of suicides in agricultural or industrial settings involved the use of OPs.
Also, even after the global prohibition of the use, production, and storage of weapons of
mass destruction (OPCW, 2005), OP nerve agent such as sarin is still used worldwide in
wars. For example, it was reported by the United Nations that 1,300 civilians died due to
OP poisoning after the use of sarin nerve agent in Syria in 2013 (United-Nations, 2013). In
the United States of America (USA), around 8,000 OP exposure cases are reported every
year (Robb & Baker., 2019).
These OP suicide cases, exposures to nerve agents due to war, and accidental OP
poisoning cases have high mortality rate in developing countries that lack adequate and
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well-equipped medical facilities to manage OP poisoning in a timely manner (Chowdhary
et al., 2014).
Organophosphates work by stimulating the continuous production of acetylcholine
resulting in the continuous activation of muscarinic and nicotinic receptors leading to the
symptoms associated with OP poisoning. Researchers use two mnemonics, “SLUDGE”
and “DUMBELLS”, to specify AChE inhibitor toxicity symptoms: salivation, lacrimation,
urination, defecation, diaphoresis, gastric upset, emesis, diarrhea, miosis, bradycardia, and
bronchospasm. The symptoms of OP poisoning can range from mild to severe depending
on the length and strength of the exposure.
The immediate initiation of the treatment is very critical to save patients’ lives and
prevent irreversible neurological complications. Atropine Sulfate (AS) is an effective and
safe antidote used alone or in combination with other drugs for the treatment of toxicities
due to nerve agent attacks and OP pesticide poisoning (Balali-Mood & Saber, 2012). The
therapeutic effectiveness of AS against OP poisoning is based on the rapid bioavailability
of therapeutic concentrations of AS in the blood (Vijayaraghavan, 2012). AS auto-injector
(AtroPen®) is a pre-filled AS intramuscular (IM) injection that was approved by the Food
and Drug Administration (FDA) in 1973 as an antidote for OP poisoning (Vijayaraghavan,
2012). AtroPen® autoinjector is designed to be used out of the hospital with a starting dose
of 2 mg for adults then doubling the dose every 5 minutes until atropinization (a term used
to refer to the signs and symptoms of atropine toxicity) is achieved. This administration
method and regimen despite being inconvenient, has successfully saved many lives
following OP poisoning (Karakus et al., 2014). However, the use of the auto-injector is
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associated with several limitations and drawbacks. These include but not limited to its
availability, cost, and administration convenience. AtroPen® is only available for veterans,
which limits its use for farmers (Bentur, Layish, & Krivoy, 2006). The autoinjectors require
training for its administration and poisoning can result in some individuals being
disoriented, hence may not be able to self-administer the drug as instructed (Topal et al.,
2014). The cost of the device limits its availability to many potential patients, especially
that more than one device are needed for the treatment of OP poisoning. Additional
drawbacks for using AtroPen® auto-injector include, patients’ body weight that can reduce
medication effectiveness for overweight and obese patients (Palma & Strohfus, 2013) and
the fear of the needle that can cause a delay in the administration, which is very critical for
the treatment of emergency medical conditions (Altman & Wood, 2014).
A new route for administering AS is being sought in order to overcome the limitations
and drawbacks associated with the use of AtroPen® auto-injector and to increase the
availability of AS as OP antidote. The sublingual route is one of the non-invasive routes of
administration that has been used for the administration of drugs in emergency conditions
and for the administration of highly metabolized drugs. However, the significance of the
sublingual route depends on the feasibility of the immediate absorption of administered
drug following its placement under the patient’s tongue. Sublingually administered drugs
get absorbed through the reticulated vein in the lining mucosa in the oral cavity, then get
transported to the facial, jugular, brachiocephalic veins, and finally to the systemic
circulation (Kweon, 2011). AS sublingual administration appears to be a promising
solution for most of AtroPen® drawbacks. It requires simpler manufacturing processes that
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would be more cost-effectiveness than the auto-injectors currently used for the first-aid
treatment of emergency OP poisoning conditions (Aodah, Bafail, & Rawas-Qalaji, 2017).
The formulation of AS as fast disintegrating sublingual tablets (FDSTs) may offer better
patient accessibility due to their lower cost, administration convenience, non-invasive
administration when multiple doses to be administered, and storing and handling flexibility
by the patient due to their small size compared to the auto-injectors, especially during
emergency conditions (M.M Rawas-Qalaji, Simons, & Simons, 2007). These tablets can
also be administered without prior training or assistance by a trained medical professional.
Due to all the previous advantages for FDSTs, a preliminary AS FDSTs were developed
and evaluated as an alternative, non-invasive dosage form for the treatment of OPs acute
toxicities (Aodah et al., 2017).
A range of AS doses, 2 mg, 4 mg and 8 mg, were previously formulated and evaluated
as AS FDSTs (Aodah et al., 2017). However, the increase in AS dose up to 8 mg has
negatively impacted the FDST’s physical characteristics. For example, in an aliquot of 2
mL of water, the FDST’s disintegration time was significantly increased up to 3 min and
AS dissolution was significantly reduced to 30% during the 1st min of the test when AS
dose was increased to 8 mg in formulated FDSTs. Additionally, the sublingual permeation
of AS had a lag time of 5 min, which can negatively impact the onset of action of AS
(Aodah et al., 2017). Because of these formulation and permeation limitations, the potential
of optimizing AS FDSTs formulation using a quality-by-design (QbD) approach were
investigated to achieve an efficient AS sublingual delivery.
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The absorption of the drug from the sublingual area can be affected by many factors.
However, the most important two main factors are: the type of formulation used as well as
the drug’s physicochemical properties (Meanwell, 2011). The types and grades of the
excipients used in a drug formulation, mainly the filler excipient, can significantly impact
drug absorption through controlling the rate of tablet disintegration into fine particles and,
therefore, controlling the rate of drug release and dissolution necessary for its absorption
(W. Brniak, Jachowicz, Krupa, Skorka, & Niwinski, 2013). Also, they are important for
localizing the released drug from the tablet formulation at the site of absorption and
limiting its loss into the stomach. Different excipients and excipients’ grades can perform
differently, especially under the very strict conditions in the sublingual cavity that lack any
agitation and has a limited volume of the saliva available for tablet disintegration and drug
dissolution (Jivraj, Martini, & Thomson, 2000). For a FDSTs formulation, disintegration
and wetting times are critical variables and can influence the rate of the drug dissolution
(Witold Brniak, Jachowicz, & Pelka, 2015). Therefore, careful selection of the excipients
that ensure rapid tablet disintegration is critical to liberate the drug and make it available
for dissolution, which can enhance the rate of drug dissolution. Therefore, the effect of
changing the filler’s grade in the AS FDSTs formulation on the tablets’ physical
characteristics was investigated in order to optimize the AS FDSTs formulation.
In order to enhance AS sublingual permeation, studying the effect of medium’s pH on
AS ionization is very important to demonstrate if modifying the sublingual medium’s pH
using a pH-modifying excipient, incorporated into the AS FDSTs formulation, can affect
the sublingual permeability of AS, and therefore, its relative bioavailability. The selection
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of excipients to be used depends on the properties of the targeted absorption site and the
drug to be administered (Goswami, Li, & Jasti, 2016). The addition of pH modifiers into
the tablet formulation to be administered sublingually ensures that the pH of the saliva is
controlled within the range that is optimal for drug absorption.
Paracellular or transcellular pathways are the two main transport pathways for any drug
to be transported into the systemic circulation through the mucosal membrane. It is crucial
to understand the dominant mechanistic transport pathways that characterize the
permeation process through the oral mucosa for different molecules. This would assist in
the selection and incorporation of the right penetration enhancer at the optimal amount to
the AS FDSTs formulation in order to enhance AS sublingual permeability and relative
bioavailability. The careful selection for the appropriate enhancer at a suitable
concentration is very critical not only to enhance AS permeability but also to ensure their
safety profile.

Research Hypothesis

It was hypothesized that incorporating a pH-modifying pharmaceutical excipient into
the FDSTs formulation would reduce the AS ionization in the tablet diffusional layer
“microenvironment” and significantly enhance its permeation through sublingual
membranes along with the assistance of a permeation enhancer.
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Research Objectives and Specific Aims

The overall objective of this research was to develop a FDSTs of AS as an alternative
and effective dosage form for the emergency treatment of OP poisoning. The specific
objective in this project was to enhance the sublingual permeability of AS by applying
multiple approaches including, optimizing the physical characteristics of AS FDSTs
formulation and enhancing AS permeability by altering the absorption microenvironment’s
pH using a pH-modifying pharmaceutical excipient and incorporating a penetration
enhancer. The specific aims to achieve this objective were as follow:
1) Evaluate the effect of the filler’s grade on the physical characteristics of AS
FDSTs.
2) Evaluate the pH-permeability profile of AS sublingual tablets.
3) Formulate and evaluate optimized AS FDSTs containing a pH-modifier to
assess their effect on AS permeability.
4) Formulate and evaluate optimized AS FDSTs containing different permeability
enhancers with or without a pH-modifier to assess their effect on AS
permeation.

Significance and Innovation

The wide-spread use of OP pesticides contributes to the high frequency of OP toxicity
that occurs worldwide. The onset of the toxicity symptoms is often within minutes, which
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can cause a number of long-term and irreversible complications. According to American
Association of Poison Control Centers (AAPCC), the number of reported exposures to OP
insecticides in the US alone were 1994 cases with 17 major outcomes and one death case
in 2016 (Katz & Brooks, 2018). The numbers of reported cases are much higher in
developing countries such as India and Nicaragua (Kanchan et al., 2010). These numbers
have been increasing every year due to the increase in in the use and exposure to these OP
pesticides. The main basic and initial treatment for the treatment of acute OP poisoning is
the immediate administration of AS, a drug that inhibits the action of excess acetylcholine
(ACh) at parasympathetic nervous system. AtroPen®, an AS auto-injector, has been
approved by FDA and considered as an effective and safe antidote used alone or in
combination with other drugs for treating OP acute toxicity. In order to overcome the
aforementioned drawbacks of using AtroPen® auto-injector and to increase the availability
and accessibility of AS as an antidote for OP poisoning, the sublingual route for AS
administration has been explored by our group (Aodah et al., 2017).
The development of AS FDSTs will provide an accessible and non-invasive first-aid
antidote for the treatment of OP poisoning and reduce the number of fatalities due to nerve
gas attacks or OP pesticide poisoning. More people in danger of OP-induced toxicities will
have access to the treatment and as a result, less fatalities and less neurological
complications will occur if this new treatment was accessible and started early, as a firstaid treatment, until patient is transported to a hospital.
The basics of our research relies on the fact that sublingual lining has a highly
networked blood vessels that aids in fast drug absorption to the systemic circulation
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(Swarbrick, 2006). Also, using FDST formulations that release drug in 10-30 sec and
promote drug dissolution in 1 min will provide non-invasive, user friendly, and more costeffective alternative treatment for OP toxicity that require no prior training for its
administration, which overcome most of the drawbacks associated with AtroPen®.
Evaluating the pH-permeability profile of AS and then incorporating a pH-modifier
excipient in order to alter the Microenvironment pH to enhance absorption and reduce
individual absorption variability, can overcome the sublingual permeability limitations
encountered at high AS FDSTs dose. The addition of chemical penetration enhancers are
another way that was studied and added to the AS FDSTs formulation to enhance its
transcellular and/or paracellular sublingual permeability in order to improve its in vivo
absorption to deliver therapeutic quantities of AS to the systemic circulation using the
sublingual route.
The development of new FDST formulations with enhanced permeability is a
promising step to reach the therapeutic blood concentration needed for OP treatment. This
novel dosage form can have a clinical significance as an alternative and non-invasive
dosage form for treating OP toxicity.

23
Assumptions, Barriers and Limitations

Assumptions

Based on the literature, the porcine sublingual membrane (PSM) shares comparable
anatomical and physiological properties with human sublingual membrane (Birudaraj,
Berner, Shen, & Li, 2005; Goswami, Kokate, Jasti, & Li, 2013; Ong & Heard, 2009; VolzZang, Waldhauser, Schulte, & Palm, 1995). Therefore, PSM was selected to be used in our
ex vivo permeation experiments.

Barriers

In this research project, some of the United States Pharmacopeia (USP) quality control
tests were not suitable to be used as standardized tests or methods to evaluate the quality
of our developed FDST formulations or to differentiate between them. For example, the
USP disintegration time test (DT) is more suitable for regular tablets, which, unlike orally
disintegrating tablets (ODTs), require a longer time to disintegrate, a higher volume to
dissolve, and vigorous agitation that resemble the stomach motility (USP/NF, 2018a).
Therefore, a previously developed apparatus were used to evaluate the DT of AS FDST
formulations that was adapted instead of the USP Disintegration test (Aodah et al., 2017).
A previously developed and validated drug dissolution (DD) test is another example of a
non-USP method used in this research to evaluate the AS dissolution from FDSTs in 60
sec (Rachid, Rawas-Qalaji, Simons, & Simons, 2011).
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Membrane integrity was one of the most important variables that can affect the results
of the drug permeation. However, in the research, the variability of the membranes due to
integrity issue was decreased by increasing the number of the replications in the experiment
(n number) and excluding outlier membranes, if any. Each ex vivo permeation study was
performed using six replicates (n=6), however, only 4 replicates (n=4) were reported by
removing data from membranes that showed excessive permeability indicating for
membrane integrity issue. If all membranes had good integrity, data from the highest and
lowest permeating membranes were excluded to maintain equal n number between
experiments. A reasonable sublingual membrane’s variability is expected and can reflect
the real biological differences between people. Permeability markers like propidium iodide
(PI), Yo-Pro-1, and trypan blue have been used before to determine membrane integrity
and exclude failing membranes (Bowman, Nesin, Pakhomova, & Pakhomov, 2010).
However, this approach requires adding the marker to all the permeability experiments
performed, then the quantification of the marker in addition to AS in the collected samples
to identify failing membranes. Then relate the experiment for the membranes that had
integrity issue. For the large amount of permeability studies performed in the project, this
approach will add significant unnecessary work, complexity, analysis, and would consume
more time. Therefore, this approach was simpler and achieved similar sensitivity and
outcome in detecting membrane integrity issues.
The addition of pH-modifier and penetration enhancers into AS FDSTs formulation
can lead to a local irritation of the tissue when the tablets are administered sublingually.
Therefore, the excipient were carefully reviewed for their safety profile before being
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selected. The amounts or concentrations reported in the literature to be safe and induced
no local toxicities were adapted and used in our AS FDST formulations to ensure the safety
of developed tablets and decrease any potential irritation or side effects that can affect the
site of administration.

Limitations

Incorporating a pH-modifier with or without a penetration enhancer into AS FDSTs
formulation to modify the microenvironment’s pH and enhance AS sublingual
permeability can be a very promising approach to achieve optimal AS sublingual
absorption. In vivo pharmacokinetic studies using these optimized AS FDSTs can confirm
the obtained ex vivo permeability studies, however, due to the lack of the animal facility
and the analytical equipment to conduct pharmacokinetic studies and analyze collected
blood samples it was not feasible to perform such studies.

Chapter Summary

The fact that high annual OP poisoning cases due to agricultural and household
accidental exposures, military and terrorist use, or suicidal cases was the main rational
behind this research project. The aim of the project was to optimize the physical properties
of AS FDSTs formulation and enhance the AS sublingual permeability and absorption to
achieve our ultimate goal of delivering therapeutic quantities of AS to the blood using the
sublingual route. These AS FDSTs will offer a novel approach for the treatment of OP
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toxicities due to the significant advantages that the sublingual route offers and the use of a
novel delivery system, FDSTs, to disintegrate, release, and promote the dissolution of AS
in 1 min or less. Also, the novelty of this dosage form is that it will be the first alternative
and non-invasive dosage form designed for self-administration for the treatment of OP
poisoning, which will offer more clinical significance compared to AtroPen®.
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Literature Review

Chapter Overview

In this chapter, literature review was carefully conducted to include the most important
and up to date information pertinent to this research project. The mechanism of action for
OP, its poisoning effects and symptoms, and the currently available treatment options in
the market were reviewed and discussed in detail.
The backbone for all treatment regimens used for acute OP poisoning is AS. AtroPen®,
a pre-filled AS auto-injector, is a single use device that can be self-administered
intramuscularly. However, the use of AtroPen® is limited due to the challenges associated
with its size (range from 10 to 14 cm) that limits the number of devices that can be carried,
handled, and stored since multiple injections are required to treat OP toxicity. The use of
the auto-injector in countries with low socioeconomic levels that have high risks of OP
poisoning is challenging due to their high cost and the required training for their
administration. This motivated us to develop a user-friendly alternative dosage form that
can offer several advantages and overcome these drawbacks.
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The sublingual route of administration was proposed as one of the promising solutions
for the several drawbacks associated with the use of AS injection. An overview of FDSTs
and their benefits to overcome the drawbacks of using AS auto-injectors were discussed.
The role of selected excipients for FDSTs formulation on the physical characteristic of
the dosage form were also reviewed. The different characteristics of various filler grades
were also reviewed in this section to guide the selection of the appropriate filler grade to
achieve optimal FDSTs characteristics for AS sublingual delivery.
The effect of pH on drug ionization and the role of pH-modifying excipients to be
incorporated into the FDSTs formulation on altering drug ionization and enhancing its
sublingual permeability were explained in detail. Also, the role of various penetration
enhancers and their mechanisms to enhance drug permeability were described.

Organophosphate Poisoning

Organophosphates are one of the most widely

used

pesticides. Today,

organophosphates have variety of uses in agriculture, homes, and as chemical gases.
Organophosphates are esters of phosphoric acid. The organophosphorus compounds share
the general structure of O=P(OR)₃ (
Figure 1) (Newmark, 2004; Zhao & Yu, 2013).
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Figure 1. General chemical structure of organophosphates.
R1, R2, and R3 represent the chemical functional groups that define the intensity of OP
action, toxicity, and physicochemical properties.

Because of the wide uses of OPs, poisoning due to the exposure to OP is more common
to occur, especially for farmers and veterans. Pesticides and nerve agents are the two main
sources for OP toxicity. According to WHO, the annual incidence rate of OP poisoning
cases to be as much as 35 per 100,000 in general population (Chowdhary et al., 2014). In
some of the agricultural countries, OPs are still the most widely used pesticides because of
their effectiveness. For example, dichlorvos, malathion, parathion methyl, and chlorpyrifos
are some of the pesticides that are used in this area (Chowdhary et al., 2014; WHO, 2004).
OP poisoning commonly occur in developing countries that lack of adequate medical care,
because they cannot afford safer but more expensive pesticides (Chowdhary et al., 2014;
Kanchan et al., 2010). For example, countries such as Sri Lanka (Gunnell et al., 2007) and
India (Kanchan et al., 2010) were registered to have the highest mortality cases due to OP
pesticides poisoning. This is because these countries have agriculture-based economies and
pesticides are commonly used and available (Chowdhary et al., 2014).
OP nerve agents such as tabun, sarin, soman, and VX have also been used as weapons
in warfare and terrorist attacks. Sarin is one of the most known OP nerve gas that was used
during the first Gulf War in 1988 and resulted in the deaths of over 40,000 people. Sarin
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gas was also used by terrorists as a weapon of mass destruction in Tokyo attacks in 1995
(Chowdhary et al., 2014). A recent account of the use of sarin gas was reported in Syria in
2012 where the Assad’s regime was accused of poisoning over 1300 people using sarin gas
(Tillman et al., 2012).

Organophosphates mechanism of action

Organophosphates mechanism of action relies on inhibiting the acetylcholinesterase
(AChE) activity, the enzyme that degrades acetylcholine (ACh) (
Figure 2), leading to the accumulation of ACh (Chowdhary et al., 2014). ACh is one of
the most abundant neurotransmitters that is found in both the central and peripheral nervous
system. So, the accumulation of ACh due to the inhibition of AChE by OP will
overstimulate the parasympathetic nervous system and muscarinic receptors (Figure 3).
This overstimulation leads to many symptoms and life threatening respiratory failure,
which is the main cause of death in OP poisoning (Eddleston, Buckley, Eyer, & Dawson,
2008; Eddleston et al., 2004). The rate and degree of ACh inhibition is related to the
structure of OP compound and its metabolism.
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Figure 2. The chemical structure of acetylcholine.
The structure is a combination of acetic acid and choline.

Figure 3. Mechanism of action of organophosphates (PEHSU, 2018).
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The severity of the toxicity following OP positing depends on the type of OP
compound, as well as, the amount and the period of the exposure. The relationship between
the structure of OP and its activity suggests that the severity of the toxicity is directly
related to the hydrophobicity of the compound (Zhao & Yu, 2013). The O=P bond in OP
competes with the carbonyl bond (C=O) in the acetyl part of ACh for the serine at the
esteratic site of AChE (Wiener & Hoffman, 2004; Zhao & Yu, 2013). The nucleophilic
hydroxyl group (-OH) on the serine residue of AChE binds to the electrophilic O=P center
of the OP that cause the formation of a very strong covalent bond (Westfall & Westfall,
2010; Wiener & Hoffman, 2004; Zhao & Yu, 2013). As a result, the phosphorylated AChE
becomes inactive and cannot hydrolyze ACh because ACh binding site is blocked by the
formed covalent bonded with OP. Therefore, this causes the inactivation of AChE, which
leads to the accumulation of ACh that cause the overstimulation of the parasympathetic
nervous system and muscarinic receptors (Sidell & Borak, 1992; Wiener & Hoffman, 2004;
Zhao & Yu, 2013) (Figure 4).

Organophosphates toxicity symptoms

The symptoms of different OPs toxicity are similar to symptoms due to the ACh overstimulation either in nicotinic or muscarinic receptors (Eskenazi, Bradman, & Castorina,
1999). Anxiety, headache, convulsions, general weakness, and depression of respiration
are commonly due to the overstimulation of the nicotinic ACh receptors. On the other hand,
symptoms like increased salivation, lacrimation, sweating, and urination are due to excess
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ACh at the muscarinic ACh receptors (Leibson & Lifshitz, 2008). Bronchoconstriction,
rhinorrhea, and diaphragm paralysis symptoms are mainly due to the autonomic nervous
system overstimulation by OP, which lead to death.

Figure 4. Mechanism of action of organophosphates toxicity.
The nucleophilic (-OH) element of the AChE binds to OP group (O=P), leading to the formation of a covalent bond between
the two molecules. This bond is strengthened when it releases an H2O molecule; this is termed the “aging” process (CDC,
2010).
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Organophosphates toxicity treatment

Numerous articles were published and established a guideline and the steps for the
treatment of OP toxicity (Eddleston et al., 2008; Eddleston et al., 2004; Mathias &
Bannister, 2013; Moshiri, Darchini-Maragheh, & Balali-Mood, 2012; Newmark, 2004;
Westfall & Westfall, 2010; WHO, 2004; Wiener & Hoffman, 2004). Since OP poisoning
is an emergency medical condition, a prompt treatment of intoxicated patient is very
critical. The treatment of OP toxicity depends on two important stages, the emergency
treatment stage and the follow-up treatment stage. The treatment steps for the emergency
treatment stage should begin at the site of exposure as follows. First, the patient must be
removed from the contaminated area and all of the soiled clothing items should be
removed. Second, airway control and adequate oxygen should be provided while checking
the breathing and heart rate of the patient. Third, the patient should be injected with AS,
which is the essential drug in every OP emergency guideline (Eddleston et al., 2008;
Eddleston et al., 2004; Wiener & Hoffman, 2004).
Co-administration of oxime derivatives shortly after atropine such as pralidoxime can
also be a part of the treatment plan. Oximes can lead to the reactivation of AChE by
trapping the phosphate group of OP to release the hydroxyl group from the esteratic site on
the AChE enzyme. The selection of the oxime molecule depends on the type OP causing
the toxicity. Also, the reactivation of AChE by oxime is only effective in a recent OP
exposure, for example, if the OP molecule has already “aged,” reactivation is unlikely to
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occur (Eddleston et al., 2008; Eddleston et al., 2004; Wiener & Hoffman, 2004). Aging is
the conversion of the inhibited enzyme into a non-reactivable form.
Following the administration of AS or the coadministration of AS with pralidoxime,
the patient need to be transferred to a medical center to start the follow up treatment stage.
Overnight hospitalization is required to monitor the patient (WHO, 2004; Wiener &
Hoffman, 2004). In some cases, the treatment can include the coadministration of
benzodiazepines with AS injection for the treatment of seizures associated with OP toxicity
(WHO, 2004; Wiener & Hoffman, 2004).
As a prophylaxis, butyrylcholinesterase (BChE) can be administered prior to OP
exposure. It is the only clinically effective prophylaxis considered for OP toxicity (Iyer,
Iken, & Leon, 2015).

Atropine Sulfate

Atropine sulfate (AS) is the sulfate salt of atropine that is extracted from the Atropa
belladonna plant (Evans, 2002; Steenkamp, Harding, Heerden, & Wyk, 2004). Atropine is
an ester consisting of tropic acid and tropine (Brown & Laiken, 2010). Because atropine
has a low water solubility, AS is the active ingredient that is used in the current dosage
forms. AS is an alkaloid with a molecular formula of [(C17H23NO3)2.H2SO4.H2O] (Figure
5), and molecular weight of 694.84. Its pKa is 9.8 and the pH for a 2% AS solution in water
is 4.5 to 6.2. An aliquot of 1 mL of water can dissolve up to 2.5 g of AS substance (RSC,
2013).
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Figure 5. Chemical structure of atropine sulfate.

Atropine sulfate mechanism of action and clinical indications

AS acts as a sympathetic antagonist and binds to the muscarinic cholinergic receptors.
It inhibits the parasympathetic nervous system by preventing the activation of the
muscarinic receptors by the ACh neurotransmitter (Eddleston et al., 2008; Eddleston et al.,
2004). AS has a wide range of clinical uses. It is used in combination with diphenoxylate
hydrochloride (2.5 mg Diphenoxylate hydrochloride USP and 0.025 mg Atropine sulfate
USP) as a tablet dosage form (Lomotil®) as adjunctive therapy to treat diarrhea or bowl
syndrome (RxList, 2018). Atropine 0.4 mg is also administered orally as anticholinergic
and antispasmodic agent (MedScape, 2018). As an ophthalmic drop solution, it is used for
cycloplegia and to induce mydriasis (Elsevier, 2015). As an injection, it is used
preoperatively to reduce salivation and bronchial secretions during surgery (Elsevier,
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2015). Also, as injection, it is used as antidote for the treatment of cholinergic toxicity
associated with OP exposure (Heath, 2002; Meridian, 2016; Wiener & Hoffman, 2004).

Atropine sulfate pharmacokinetics and pharmacodynamics

According to the clinical studies, AS’s distribution kinetics are dose-dependent. As a
result, for the emergency treatment of OP toxicity, multiple administrations of AS are
required to reach the effective concentration needed for the treatment. Based on the
biopharmaceutics classification system (BCS), drugs can be classified depend on their
solubility and permeability into four classes, high solubility-high permeability (Class I),
low solubility-high permeability (Class II), high solubility-low permeability (Class III),
and low solubility-low permeability (Class IV). AS is considered as a class III based on the
BCS classification (Custodio, Wu, & Benet, 2008). AS is a highly soluble salt in water (2.5
g/mL) that exhibited first-order elimination kinetics with renal plasma clearance of 660
mL/min (Hinderling, Gundert-Remy, & Schmidlin, 1985; Lindenberg, Kopp, & Dressman,
2004).
After oral administration, atropine appears in plasma after 15 min and the Cmax is
achieved within 1.5 – 4 hours. About 90% of a 2 mg oral dose was found to be absorbed
through the gastrointestinal tract (GIT) (McEvoy, 2012 ). The half-life (T1/2) of atropine
intravenous (IV) administration is (mean ± SD) 3.0 ± 0.9 hours (NIH, 2016).
For our-of-the hospital treatment of OP toxicity, the recommended starting dose for an
adult is 2 mg using AtroPen® auto-injector, and then doubling the dose every 5 minutes
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until atropinization is achieved, with a maximum use of 3 auto-injectors. A 2 mg dose will
results in a Cmax of 9.6 ± 1.5 ng/mL (mean ± SEM) and a Tmax of 3 min (NIH, 2016).
AS can be used alone or in combination with other drugs for the treatment of OP
toxicity. However, most of these combinations have more side effects. For example, the
coadministration of pralidoxime with AS can lead to increased respiratory complications
and higher mortality. Also, the coadministration of benzodiazepine such as diazepam with
AS showed a poor intramuscular (IM) absorption (Eddleston et al., 2008; Eddleston et al.,
2004; Meridian, 2016).
Most of the adverse effect associated with atropine is due to its antimuscarinic action.
These include dry mouth, blurred vision, tachycardia, palpitation, headache, nausea, and
vomiting. AS induces changes to the heart rate and respiratory passages based on the dose
administered (Elsevier, 2015). After the administration of 0.5 mg AS, the excessive
secretions from mouth and skin were stopped and dried up. Doubling the dose to 1 mg AS
can increase the heart rate and mildly enlarges the pupils. With a dose of 2 mg AS, sever
dry mouth, palpitation, and pupil dilatation accompanied by paralysis of accommodation
may occur. A 5 mg AS dose can cause a more intense effects. These include, headache,
difficulty in urinating, and slow gut movement. By increasing the dose to 10 mg AS or
above, hallucination, arrhythmia, coma, and respiratory depression may occur as a result
of the reduction in the secretions in respiratory passages that leads to a constriction
and spasm of the respiratory passages, which can lead to death (Brown & Laiken, 2010;
Heath, 2002; Meridian, 2016). The administration of AS for children should be used
carefully as they are more sensitive to its adverse effects (Elsevier, 2015).
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Atropine sulfate auto-injector

The AtroPen® auto-injector is designed for self or caregiver administration. Each unit
is composed of a needle inside a cartridge that is 21 mm long for the 2 mg, 1 mg, and 0.5
mg units or 13 mm long for the 0.25 mg unit. The drug delivery begins at the moment
the needle emerges from the cartridge. After the use of the AtroPen®, the container should
be disposed and cannot be refilled and the protruding needle cannot be retracted (NIH,
2016).
AtroPen® are manufactured as AS 0.25 mg (for infants weighing less than 15 pounds
(lbs)), AS 0.5 mg (for Children weighing 15 lbs to 40 lbs), AS 1 mg (for Children weighing
40 lbs to 90 lbs), or AS 2 mg (for Adults and children weighing over 90 lbs) by Meridian
Medical Technologies (Meridian, 2016; NIH, 2016) (Figure 6). Each strength provides
different amount of atropine in either 0.3 mL or 0.7 mL sterile solution containing glycerin,
phenol, citrate buffer and water for injection. AtroPen® 0.25 mg provides 0.21 mg
atropine/0.3 mL, AtroPen® 0.5 mg provides 0.42 mg atropine/0.7 mL, AtroPen® 1 mg
provides 0.84 mg atropine/0.7 mL, and AtroPen® 2 mg provides 1.67 mg atropine/0.7 mL
(NIH, 2016).
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Figure 6. Image of atropine sulfate auto-injector devices (AtroPen®) (Hilmas & Hilmas,
2009).

AtroPen® alone is the basic treatment used against acute OP poisoning. This autoinjector is designed to be injected through the IM route to deliver AS. AtroPen® should be
administered firmly straight down a 90° angle against the outer thigh. The current dosage
form and administration method have successfully saved many lives from organophosphate
poisoning. However, it is still inconvenient and unavailable in many developing countries
and for farmers (Chowdhary et al., 2014). AtroPen® auto-injectors mainly available for
military use in some countries and is not available for public use (Gunnell et al., 2007;
Kanchan et al., 2010), which limit their use by farmers and civilians who are at risk of
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nerve gas attacks. As stated previously, the use of the auto-injector, when available, is
associated with several drawbacks. Their large size makes them difficult to carry and limits
the number of devices that can be stored at any given time since multiple injections are
required to administer the required doses of AS to achieve atropinization. Due to the
multiple AtroPen® administration required to treat OP poisoning, they are considered
highly invasive and are associated with increased risks of administration errors and
infections, which may limit their effectiveness in practice. Because the needle cannot be
retracted after administration this can lead to a possible post administration injuries (NIH,
2016). Many IM injections, including AtroPen® may result in poor absorption which can
reduce the drug effectiveness in obese (overweight) patients. This is due to the fixed needle
length used in AtroPen®, which may not go deep enough to reach deep into the muscle
(Palma & Strohfus, 2013). The use of these auto-injectors is very challenging in countries
with low socioeconomic levels and have high risks of OP poisoning due to their high cost
($37 per device), the required prior training for their administration, and the lack of
adequate and well-equipped health care facilities in rural areas where majority of the OP
toxicity cases occur (Ingle & Agarwal, 2014).

Alternative dosage forms for atropine sulfate administration

In order to increase the availability of AS as an OP antidote, new routes of
administration for the systemic delivery of AS are being sought that can avoid the
drawbacks associated with the use of AtroPen® auto-injectors. One key aspect of the
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selection of these new routes is to offer alternative noninvasive administration methods
that can be used for multiple drug administrations. Also, these alternative administration
methods or developed dosage forms have to be accessible to the individuals in low-income
regions, farms, rural areas, and countries with ongoing armed conflicts. Upon reviewing
the literature, three different dosage forms have been investigated and tested for this
purpose as follow:
1. AS respiratory inhaler:
As respiratory inhaler was one of the dosage forms that were designed and
evaluated (Corcoran, Venkataramanan, & Hoffman, 2013). According to the
study, five puffs of AS inhaler were needed to deliver AS dose equivalent to
AS 2 mg IM injection dose. The study concluded that an AS inhaler can be used
only as an adjunctive therapy after the auto-injector (Corcoran et al., 2013).
Another inhaler using Nano-AS dry powder was designed and evaluated by Ali
et al. (2009). The authors conducted a clinical trial, and based on their results,
a 6 mg of AS delivered via an inhaler was had a pharmacokinetic profile
equivalent to AS 2 mg IM injection (Ali, Jain, & Iqbal, 2009).
2. AS nasal aerosol spray:
According to the study performed by Kumar et al. (2001), AS was delivered
using a nasal spray in rats to study the cardiovascular and respiratory variables
for OP toxicity. The results concluded that using AS nasal spray is as effective
as an intraperitoneal injection (Kumar, Vijayaraghavan, & Singh, 2001).
3. AS sublingual injection:
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AS sublingual absorption was evaluated for the emergency treatment of OP
toxicity by injecting AS eye drop solution formulation (Minims® 1%) under the
tongue. The results showed that the time needed to reach the maximum
concentration after sublingual injection (Tmax) was less than the time after IM
injection of AS (Rajpal, Ali, Bhatnagar, Bhandari, & Mittal, 2010). In spite of
the promising results this administration method is perceived as very invasive
and not practical for self-administration.
However, AS sublingual administration appears to be a promising solution
for most of AtroPen® drawbacks. Therefore, preliminary AS FDSTs for the
potential treatment of OP toxicity were developed, as reported previously
(Aodah et al., 2017).

Sublingual Route of Administration

The sublingual route of administration is one of the efficient routes that can be used for
treating emergency conditions. The significance of this route is due to the feasibility of the
drug’s immediate absorption after its placement under the tongue. The blood in the
reticulated veins in the oral mucosal lining absorbs and transports the drug to the facial,
jugular, brachiocephalic veins and finally to the systemic circulation (Kweon, 2011)
(Figure 7). The sublingual mucosa is the thinnest mucosal lining of all oral mucosal area,
highly vascularized, has low membrane’s thickness (100 to 200 µm), and low
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keratinization, which promotes rapid drug absorption and onset of action, bypassing the
first hepatic metabolism (Teubl et al., 2013) (Figure 8).

Figure 7. The Sublingual Region (Ardent, 2018).
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Figure 8. Movement of Drug Across Sublingual Mucosa (Dev, Mundke, Pawar, &
Mohanty, 2016).

Fast disintegrating sublingual tablets

Fast disintegrating sublingual tablets are solid dosage form that dissolve or disintegrate
under the tongue without water within 1 min or less (USB/NF, 2018). ODTs in general are
a user-friendly drug delivery system that helps patients such as geriatrics and children, with
swallowing problems, by combining the advantages of the ease of the oral administration
of liquids and the practicality of tablets administration (Senel, Rathbone, Cansiz, & Pather,
2012). Sublingual administration through FDSTs offers many advantages when it comes
to treating emergency conditions. The tablets can be administered immediately as a first-
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aid treatment right after the occurrence of the incident and until patient is transported to an
emergency room or an equipped health care facility.
The first-aid administration of these tablets would allow for an early initiation of the
treatment and reduction in complications and patient death. These tablets need no water to
disintegrate or drug to dissolve, which can avoid a critical limiting step for their first-aid
administration in emergency treatment. They offer more administration convenience and
storing and handling flexibility for patients due to their small size (M.M Rawas-Qalaji et
al., 2007). These tablets also can be administered without prior training or the assistance
of a trained medical professional (Singh et al., 2012). Sublingual tablets production is
similar to production of most of other solid dosage forms that require simple and costeffectiveness manufacturing processes (Aodah et al., 2017). Formulating drugs to be
administered sublingually as FDSTs ensures rapid tablet disintegration and drug release,
which is important in the emergency conditions.
One of the earlier examples of sublingual drug administration for the treatment of an
emergency clinical condition is nitroglycerin sublingual tablet, which is used for the
treatment of angina (Divakaran & Loscalzo, 2017). It relies on rapid drug release and onset
of action. The sublingual route for the administration of nitroglycerin sublingual tablet
elicits a drug response within 1-3 minutes after its administration (Divakaran & Loscalzo,
2017). Verapamil is another example used for the treatment of angina that has shown to
elicit a quick response when administered sublingually (Al-Waili & Hasan, 1999; John,
Fort, Lewis, & Luscombe, 1992).
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Atropine sulfate fast disintegrating sublingual tablets

The formulation of the aforementioned AS FDSTs (Aodah et al., 2017) was adapted
from a previously prepared epinephrine FDSTs formulation (M. M. Rawas-Qalaji, Simons,
& Simons, 2006). The doses used in the previous AS FDSTs ranged from 2 mg to 8 mg
with a total tablet weight of 50 mg (Aodah et al., 2017). These tablets were developed as
potential alternative dosage form for OP acute toxicity treatment. All the AS FDSTs
batches passed the quality control test. However, when the AS dose was increased from 2
mg to 8 mg, the tablet formulation’s properties deteriorated. For example, the disintegration
time for the tablet was increased up to 3 min. Also, only 30% of the drug dissolved in 1
min (Aodah et al., 2017). Therefore, the compression force used to manufacture 8 mg AS
tablets was reduced from 130 -150 kgf to around 90 kgf in order to improve tablet
disintegration and AS dissolution (Aodah et al., 2017). Also, the sublingual permeability
of AS using this preliminary tablet formulation resulted in a lag time of 5 min. This means
that the start of AS sublingual permeability was delayed by 5 min, which can negatively
impact the potential of using these tablets as antidote for OP toxicity, which require a fast
onset of action (Aodah et al., 2017). Due to these limitations, the previous preliminary
tablet formulation was optimized in this work and then the optimized FDSTs were
characterized using a quality-by-design approach to overcome the aforementioned
limitations and to increase the potential of using AS FDSTs as a non-invasive, userfriendly, and cost-effective AS dosage form for the treatment of emergency OP poisoning.
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Excipients

Pharmaceutical excipients are pharmacologically inactive ingredients added to the drug
formulation and form part of the finished product (Chen, Chetty, & Chien, 1999). The
absorption of the drug from the sublingual area is affected by many factors. Some of the
main factors include the type of formulation used, including excipients, as well as the
drug’s physicochemical properties (Meanwell, 2011). Excipients in a drug formulation
play an important role in determining the rate of drug absorption through the mucosa by
controlling the rate of tablet disintegration into small particles and, therefore, controlling
the rate of drug release and dissolution necessary for its absorption (W. Brniak et al., 2013).
Also, in comparison to a liquid formulation, excipients in a sublingual tablet formulation
are important for localizing the formulated drug at the site of absorption and limiting its
loss into the stomach.

Effect of excipients on the physical characteristics of FDSTs

Different excipients can perform differently under very strict conditions like the
sublingual cavity that lacks any agitation and has limited volume of saliva to facilitate
tablet disintegration and drug dissolution (Jivraj et al., 2000). For FDSTs formulation,
disintegration and wetting times are critical attributes that can influence the rate of drug
dissolution (Witold Brniak et al., 2015). Therefore, selecting excipients that ensure rapid
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tablet disintegration is critical to liberate the drug and make it available for dissolution,
which can lead to enhancing the rate of drug absorption.
Most of the physical characteristics of FDSTs such as hardness, disintegration time,
and powder flowability can be affected by the type of excipients used and their percentages.
For example, Watanabe et al. (1995) used microcrystalline cellulose (MCC) grade PH-301
and Low-substituted hydroxypropyl cellulose (L-HPC) grade LH-11 in their studies. Their
results showed that increasing the percentage of LH-11 from 10% to 30% resulted in a
reduction in the tablet hardness from 8 kgf to 6 kgf, and an increase in their disintegration
time. Also, increasing the percentage of LH-11 (beyond 30%) reduced the powder’s
flowability (Watanabe et al., 1995). Additionally, excipients selected for FDSTs
formulation have to have low moisture content and low water solubility to ensure drug
stability and enhance tablet disintegration and drug dissolution (Alyami et al., 2017).

Microcrystalline cellulose

The MCC and L-HPC were the two cellulose excipients used in our AS FDSTs
formulation (Aodah et al., 2017). MCC is a filler that is produced in wide variety of grades
with different range of particle sizes and shapes, moisture contents, angle of reposes, and
porosities (Guy, 2009). Each grade offers various set of properties that can affect the overall
characteristics of the formulation. For example, MCC’s particle size and shape are the two
important variables that can influence the entire powder flowability. MCC the PH grade is
one of the most widely used grade in tablet formulations. Later, the MCC UF grade was
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introduced as a new highly compressible filler grade. The different properties of different
grades of MCC are shown in Table I (Asahi, 2018).
For FDSTs formulation, the filler is one of the most important excipient that represents
the highest percentage incorporated into the tablet formulation (Moolchandani et al., 2015).
Since the preliminary AS FDSTs formulation resulted in unfavorable tablet’s hardness and
disintegration time characteristics at high AS dose, it has been proposed that altering the
filler type or grade in this project can improve the overall physical characteristics of the
tablet, which can influence drug dissolution and absorption (Horio, Yasuda, & Matsusaka,
2014).

Table I. Characteristic of different MCC Filler Grades (Asahi, 2018)
Average
Bulk Density
Loss on
Particle Size
MCC Grade
3
(g/cm )
Drying (%)
(µm)
UF-702
90
0.29
2.0-6.0

Repose Angle
(degree)
34

UF-711

50

0.22

2.0-6.0

42

PH-101

50

0.29

2.0-5.0

45

PH-102

90

0.30

2.0-5.0

42

PH-200

170

0.35

2.0-6.0

36

PH301

50

0.41

2.0-6.0

41

PH302

90

0.43

2.0-6.0

38
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Role of pH in Enhancing AS Sublingual Permeability

The pH of the drug and its degree of ionization are critical parameters that can affect
the drug permeation and absorption through the mucosal membrane. The pKa of the drug
and the pH at the site of drug absorption in the sublingual region affect the extent of drug
ionization and therefore, its permeability and absorption. The physiological pH in the
sublingual area ranges between 5.8 to 7.5 (Sattar, Sayed, & Lane, 2014). Therefore, drugs
that are unionized or partially ionized at this pH and with acceptable lipophilicity and low
molecular weight can be readily absorbed through the sublingual mucosa (Wang & Chow,
2014). The less the drug is ionized the more it can easily pass through the sublingual
mucosal phospholipid layer (Chen et al., 1999). In general, most of the drugs are either
weak basic or weak acidic, which means that they are partly ionized, hence, can attract
water molecules, forming large complexes that cannot pass through the pores in the
semipermeable membrane (Goswami et al., 2016). However, the degree of ionization of
weak basic or acidic drugs is based on the prevailing pH at the site of absorption.
According to Lee et al. (2005), the permeability of different compounds were tested
using different apical pH buffer. The permeability of the basic compounds such as
propranolol and timolol was decreased when the apical pH changed from 7.4 to 6.5 (Lee
et al., 2005). Also, when the permeability of cimetidine (pKa= 6.8) and alfentanil (pKa=
6.5) were tested at different pH in Caco-2 cells monolayers, their permeability were
increased 30 – 60 fold at pH 8.0 in comparison to pH 5.0 (Palm, Luthman, Ros, Grasjo, &
Artursson, 1999).
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Altering the absorption medium’s pH in order to enhance drug bioavailability of basic
drugs can be achieved by incorporating alkalinizing excipients into the drug formulation.
The selection of the excipients to be used depends on the properties of the target absorption
site (Goswami et al., 2016). Additionally, the addition of an alkalinizing excipient, also
called a pH-modifier, to the tablet formulation to be administered sublingually ensures that
the pH of the saliva is controlled within the range that is optimal for drug absorption and
reduces absorption variability due to individual differences or food effect. The selection of
these excipients is particularly important for AS as a weak base (Hassan, Ahad, Ali, & Ali,
2010). Its extent of absorption can be greatly dependent on its degree of ionization, which
is mainly affected by the pH of the saliva (Goswami et al., 2016). Therefore, the evaluation
of various pH-modifying excipients is critical for enhancing and optimizing AS
permeability.

Calcium carbonate

Calcium carbonate (Ca Carb), CaCO3, is a white inorganic water soluble salt. It forms
a moderately alkaline solution when it dissolves in water. Its molecular weight is
100.09 g/mol, with a melting point of 1571°F (825°C) (USP/NF, 2018i). Ca Carb is used
therapeutically as a buffer in hemodialysis. It can be used as antacid for temporary
heartburn relief. Ca Carb is also frequently used as a calcium supplement for osteoporosis
treatment (MeSH, 1965).

54
Sodium citrate

Sodium citrate (Na Cit), Na3C6H5O7, is a white water soluble salt. It can be prepared
as mon, di, or tri sodium citrate. Its molecular weight is 214.10 g/mol, with a melting point
of 414°F (212°C) (USP/NF, 2018k). It can be used to increase the free sodium load. Na Cit
is widely used as a buffer to adjust the pH of weak acidic or weak basic drugs (Ugwu &
Apte, 2004).

Sodium bicarbonate

Sodium bicarbonate (Na Bicarb), NaHCO3, is a white solid powder usually known as
baking soda. It is a strong base that generates sodium carbonate when it heats over 200°F
in oven for about an hour. Its molecular weight is 84.01 g/mol, with a melting point of
122°F (50°C) (USP/NF, 2018j). It is one of the most commonly used pH buffering agent.
Na Bicarb is also used as antacid to treat heartburn, indigestion, and upset stomach by
neutralizing the excess stomach acid (MeSH, 1994).

Role of Penetration Enhancers in Enhancing AS Sublingual Permeability

Properties of drugs such as lipid solubility and molecular weight have been reported to
affect the absorption of the drug (Gao & Morozowich, 2006). It is very important to
understand the mechanistic analysis and the characteristics for the permeation process in
the oral mucosal for drugs of interest to optimize their drug delivery. The paracellular and
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the transcellular routes are the two major pathways for any drug in order to pass through
the mucosal membrane. The preferred pathway for most ionizable molecules will depend
on two factors, the charge status of the molecule and the resistance encountered during the
permeation process (Chen et al., 1999).

Transcellular transport

The drug movement via the transcellular route involves the following: drug transport
across the luminal membrane, diffusion through the cytosol, transport across the basolateral
membrane, and movement through interstitial fluid and capillary (Patel & Misra, 2011).
Transcellular permeation enhancers work by promoting the disruption in the cellular
membrane. These enhancers, such as surfactants, partition into the cellular membranes and
disrupt the packing of the lipids which results in defects in the structural integrity of the
membrane (
Figure 9). However, their concentrations to be used are critical to avoid associated
cytotoxicity.

Paracellular transport

Paracellular transport is a passive transport where the substance transfers across the
epithelium cells through the intercellular spaces between cells (Maiti, 2017). Tight
junctions between cells play an important role in paracellular permeation. Unlike
transcellular transport, paracellular transport is less selective with respect to size, charge,
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and hydrophobicity (Preusch, 2007). It is the suitable way for hydrophilic substances that
are not able to permeate through transcellular transport. Paracellular penetration enhancers
have the ability to enhance drug absorption through transient widening of the tight
junctions of the cells in the membrane leading to reducing in their resistance and increasing
permeability while decreasing cell viability (Goswami et al., 2016) (
Figure 9). It is also known that the paracellular pathway is more selective to positively
charged molecules than negatively charged molecules (Caon, Jin, Simoes, Norton, &
Nicolazzo, 2015). Some of these enhancers can work as a mucoadhesive as well, which
can potentially prolong the retention of the drug at the site of absorption and minimize drug
loss by salivary secretions in sublingual area.

Figure 9. Transcellular and Paracellular Transport (Levendoski, Leydon, & Thibeault,
2014).
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Sodium dodecyl sulfate

Sodium dodecyl sulfate (SDS) is a synthetic surfactant that enhances the absorption of
the drugs through the sublingual mucosa by modifying the permeability of biological
membranes and through the interaction with the drug (Goswami et al., 2016). SDS works
as a transcellular enhancer that enhances the absorption of the drug due to protein
denaturation, enzyme inactivation, swelling of tissue, and extraction of lipid components
(Goswami et al., 2016). It also works as a paracellular enhancer by increasing the
absorption of the hydrophilic drugs through the paracellular route through the
solubilization of the intracellular lipids that form a barrier to paracellular permeant. The
effects of SDS as penetration enhancer depend mainly on the lipophilicity of the permeant.
It showed a very promising effect when used for the buccal drug delivery (Nicolazzo, Reed,
& Finnin, 2004). On the other hand, SDS is a powerful irritant at high concentrations,
however, a 1% SDS concentration was reported as the maximum concentration that can be
used without causing cytotoxicity ("Final Report on the Safety Assessment of Sodium
Lauryl Sulfate and Ammonium Lauryl Sulfate," 1983).

Palmitoyl carnitine chloride

Palmitoyl carnitine chloride (PCC) is a fatty acid derivative of L-carnitine that works
as an enhancer of hydrophilic molecules (Duizer, van der Wulp, Versantvoort, & Groten,
1998). It enhances the absorption of the drug by distributing the epithelial tight junctions,
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which reduces the resistance and increases the permeability while decreasing cell viability.
It also causes dilation in the paracellular spaces. Duizer et al. (1998) studied the correlation
between the absorption enhancing effect of PCC and its effect on tight junction morphology
and cytotoxicity on the intestinal epithelium. They found that PCC was able to decrease
the transepithelial electrical resistance (TEER) for hydrophilic molecules and increase their
absorption and permeation (Duizer et al., 1998). The effect of PCC as an enhancer is a dose
dependent, which means that by increasing the concentration of PCC, its effect as
absorption enhancer increases (Duizer et al., 1998; Sutton, LeCluyse, Engle, Pipkin, & Fix,
1993). The maximum reported concentration that can be used without causing cytotoxicity
is 1mM (Duizer et al., 1998).

Sodium glycocholate

Sodium glycocholate (Na Gly) is a bile salt that have been shown to be effective as a
penetration enhancer, especially in buccal epithelial mucosa. Na Gly works both as a
transcellular and a paracellular penetration enhancer. Its transcellular enhancement works
by interacting with the epithelial lipids, which cause a destruction in the lipid packing and
formation of micelles that overcomes the resistance at the aqueous diffusion layer of
epithelial cell membrane (Senel, Duchene, Hincal, Capan, & Ponchel, 1998). However, the
paracellular enhancement works by disrupting the cell-cell junction to cause widening in
tight junctions between cells (Mahaling & Katti, 2016). According to the study done by
Williams et al. (2004), 0.5% Na Gly was able to increase the permeability of
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polycaprolactone nanoparticles in the anterior part of the eye (Mahaling & Katti, 2016).
Also, Senel et al. (1998) studied the effect of Na Gly as a permeation enhancer for morphine
hydrochloride (MPH) across the porcine buccal mucosa. Two concentrations were tested
(10 mM and 100 mM). The results showed that 100 mM concentration was able to
significantly enhance the permeability of morphine at porcine buccal mucosa but not the
10 mM concentration (Senel et al., 1998).

Chapter Summary

In this chapter, the mechanism of action of OP poisoning and their signs and symptoms
were discussed. The steps for OP poisoning treatments were described. AS autoinjector is
the basic and initial pharmacological treatment for OP poisoning. However, because of the
drawbacks associated with its use, alternative route of administration was proposed. The
advantages of the sublingual route anatomy and physiology for sublingual drug delivery
were explained and the formulation of AS FDSTs was discussed. The role of the excipients
and filler grades in enhancing the physical characteristics of FDSTs formulation was
described. Finally, two different approaches to enhance the sublingual permeation of
FDSTs were reviewed. These included the use of pH-modifying agents and penetration
enhancers.
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Methodology

Chapter Overview

In order to address the objectives and aims of this research project, the methods used
were developed and performed according to the following five main steps:
1. Validating the analytical method for the quantification of AS.
2. Formulating and manufacturing various AS FDST formulations.
3. Evaluating the characteristics of AS FDSTs using various quality control tests.
4. Evaluating the ex vivo pH-permeability profile for AS FDSTs.
5. Evaluating the potential of incorporating different pH-modifiers into AS FDSTs and
their effect on AS FDSTs ex vivo permeability.
6. Evaluating the potential of incorporating different penetration enhancers into AS
FDSTs and their effect on AS FDSTs ex vivo permeability.
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Analytical Method of Atropine Sulfate

The validation of the analytical method was required for the accurate and reliable
analysis of AS samples. AS samples obtained from the quality control tests and Franz cells
permeability studies were analyzed and quantified using high pressure liquid
chromatography (HPLC) system as the analytical equipment used in this project (USP/NF,
2018h). Several AS calibration curves were prepared. Intra- and inter-assay variation,
instrument and method reproducibility, instrument injection volume accuracy, and the
minimum limit of quantification were determined to ensure that reliability of the analytical
method used.

HPLC system and detection method

In this project, an HPLC system, model e2695, Waters Corporation (Milford, MA) was
used. The system was equipped with a UV photodiode array (PDA) detector, model 2998,
a pump, a column oven, a degasser, and an auto sampler. The column used was the
reversed-phase µBondapak C18 Column, 125Å, 10 µm, 3.9 mm X 300 mm, which was
purchased from Waters Corporation (Milford, MA). A sample injection volume of 20 µL
with a pump flow rate of 2 mL/min, and a detection wavelength of 254 nm were used for
AS analysis (USP/NF, 2018g).
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Materials

The mobile phase was prepared by dissolving 5.1 g of tetrabutyl ammonium hydrogen
sulfate, purchased from Sigma Aldrich (Saint Louis, MO), in a 50 mL acetonitrile,
purchased from EMD Millipore Corp. (Billerica, MA), in a 1 L volumetric flask. The final
volume of 1 L was then completed by adding acetate buffer that was previously prepared
by adding 5.9 g of sodium acetate, purchased from Sigma Aldrich (Saint Louis, MO), in 1
L volumetric flask. Acetic acid 3 mL, purchased from Sigma Aldrich (Saint Louis, MO),
was added and the final volume of 1 L was then completed by adding deionized water to
prepare acetate buffer at a pH of 5.5. The mobile phase pH was adjusted to 5.5±0.1 with
5N sodium hydroxide, purchased from EMD Millipore Corp. (Billerica, MA), and then
filtered using 0.2 µm 47mm Supor®-200 filter (Pall Corporation, Mexico).

Calibration curves

Calibration curve is a general method used to understand the response of the instrument
to the analyte and to determine the concentration of an unknown sample analyte. The
calibration curves were prepared and used for method qualification and AS quantification.
A stock solution of AS (2 mg/mL) was prepared by dissolving 20 mg of AS monohydrate,
purchased from Sigma Aldrich (Saint Louis, MO), in 10 mL deionized water in a 10 mL
volumetric flask. A series of different AS standards were then prepared using the stock
solution, including 200 µg/mL, 160 µg/mL, 80 µg/mL, 40 µg/mL, 20 µg/mL, 10 µg/mL,
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and 5 µg/mL. Calibration factor was calculated from the slope obtained from plotting the
area under the curve (AUC) of the different AS standards against their concentrations
(n=5).

Instrument reproducibility

Measuring the instrument reproducibility is very important as it measures the ability of
the instrument to produce the same result if the same input was used. The reproducibility
of HPLC instrument was evaluated by injecting and analyzing multiple AS standards of a
high and low concentrations of AS, 20 µg/mL and 200 µg/mL (n=5). The relative standard
deviation percentage (RSD%) for the injected and analyzed AS standards were calculated.

Injection volume accuracy

The accuracy of the injection volume can measure the error that can result when using
a specific instrument (instrument error). Usually, for each instrument, there is a range of
error that can be acceptable. In order to evaluate the accuracy of the autosampler, injection
linearity test was performed. The linearity of injecting increasing volumes of 10 µL, 20
µL, 40 µL, 60 µL, 80 µL, and 100 µL of AS standard solution 20 µg/mL was evaluated by
calculating the correlation of coefficient (R2) of the slope obtained from plotting the area
under the curve (AUC) of the different injections against their injection volumes.
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Intra and inter-assay variation system

In order to evaluate the method and personal variability, intra and inter-assay variation
of AS calibration curves were performed. This test can express the precision and
repeatability of the results, which are the two important factors for instrumental and
analytical method qualification. Different calibration curves were used from three days at
different times of the day (morning and evening). For intra-assay variability, 3 sets of AS
standards for 3 different calibration curves (n=3) were prepared on the same day but at
different times and used to determine variations between the results analyzed on the same
day. For inter-assay variability, 3 sets of AS standards were prepared at different days (n=3)
and used to determine variations from day to day analysis. The RSD% for the analyzed AS
standards were calculated.

The limit of quantification

The limit of quantification (LOQ) is defined as the minimum concentration that can be
quantified accurately and reproducibly. LOQ was measured to determine method’s
sensitivity and qualify the analytical method used. Low AS standard concentrations
including: 0.1 µg/mL, 0.5 µg/mL, 1.25 µg/mL, 2.5 µg/mL, and 5 µg/mL, were injected and
analyzed (n=5). The lowest AS concentration that was detected and analyzed with an
RSD% of £ 5%, was considered the LOQ for AS using this analytical method.
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Formulation and Manufacturing of AS FDSTs

The previously prepared and manufactured AS FDST formulations were adapted
(Aodah et al., 2017) and optimized to address our aims.
For this research project, 10 different AS FDST formulations were formulated and
manufactured. All the AS FDST batches contained 8 mg AS as the active ingredient and
had a total tablet weight of 50 mg.

Materials

Atropine sulfate monohydrate (AS) was purchased from Sigma Aldrich (Saint Louis,
MO). Magnesium stearate was used as a lubricant and purchased from Alfa Aesar
(Heysham, Lancs, UK). Two grades of Ceolus® fillers MCC (PH-301) and (UF-702) were
generously provided by Asahi Kasei Chemicals Co. (Tokyo, Japan). The superdisintegrant
L- HPC (LH-11) was provided by Shin-Etsu Chemical Co., Ltd. (Tokyo, Japan).

Formulation preparation

All the powders used were sieved before mixing using an electrical sieve shaker (ColeParmer, Vernon Hills, IL) with a sieve number 140 (106 µm) to ensure all excipients and
active ingredient had uniform particles size distribution. AS was manually mixed with
MCC by geometric dilation method. L-HPC, two-third the quantity, was mixed with the
other powder mixture for 4 min using a three-dimensional manual mixer (Inversina,
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Bioengineering AG, Wald, Switzerland). Magnesium stearate and the remaining one-third
of L-HPC were manually mixed and then added to the powder mixture to be mixed for
additional 30 sec. This mixing procedure was used to achieve both internal and external
positioning of the superdisintegrant.
The composition of the ten formulations are shown in Table II. The optimized AS
FDST formulation contained the highly compressible filler grade, MCC UF-702, and was
compared to the previously used filler grade, MCC PH-301. A pH modifier, Na Bicarb, a
pH modifier and penetration enhancers, SDS, PCC, Na Gly, and enhancers alone, SDS,
PCC and Na Gly, were incorporated in the optimized AS FDST formulations (Table II).

FDSTs’ manufacturing

The mixed powder from each formulation of the ten batches was compressed and
manufactured by direct compression method using a rotary Minipress I (Glob Pharma, NJ)
at a compression force of 130-150 kgf using 3”/16” concave punches (Natoli Engineering
Company, Inc., St. Charles, MO).

50.0 (100) 50.0 (100) 50.0 (100) 50.0 (100) 50.0 (100) 50.0 (100)

Total weight (mg), mg (%)

0.00 (0)

0.00 (0)

0.00 (0)

8.00 (16.0)

7.5 (15)

0.00 (0)

0.00 (0)

0.00 (0)

0.50 (1.0)

0.00 (0)

0.50 (1.0)

4.10 (8.2)

36.90
(73.8)

8.00
(16.0)

R8

0.00 (0)

8.00 (16.0)

0.00 (0)

0.00 (0)

0.50 (1.0)

3.35 (6.7)

30.15
(60.3)

8.00
(16.0)

R9

10.00
(20.0)

0.00 (0)

0.00 (0)

0.00 (0)

0.50 (1.0)

3.15 (6.3)

28.35
(56.7)

8.00
(16.0)

R10

50.0 (100) 50.0 (100) 50.0 (100) 50.0 (100)

10.00
(20.0)

0.00 (0)

0.00 (0)

1.00 (2.0)

0.50 (1.0)

3.05 (6.1)

27.45
(54.9)

8.00
(16.0)

R7

R1: AS FDSTs using MCC UF-702; R2: AS FDSTs with Na Bicarb 2%; R3: AS FDSTs with Na Bicarb 2% and SDS 0.5%;
R4: AS FDSTs with Na Bicarb 2% and SDS 1%; R5: AS FDSTs with Na Bicarb 2% and PCC 16%; R6: AS FDSTs with Na
Bicarb 2% and Na Gly 15%; R7: AS FDSTs with Na Bicarb 2% and Na Gly 20%; R8: AS FDSTs with SDS 1%; R9: AS FDSTs
with PCC 16%; R10: AS FDSTs with Na Gly 20%.

0.00 (0)

0.00 (0)

0.00 (0)

0.00 (0)

0.00 (0)

0.00 (0)

Sodium glycholate (Na
Gly), mg (%)

0.00 (0)

0.50 (1.0)

1.00 (2.0)

0.50 (1.0)

3.30 (6.6)

0.00 (0)

0.25 (0.5)

1.00 (2.0)

0.50 (1.0)

3.25 (6.5)

29.7
(59.4)

8.00
(16.0)

R6

Plamitoyl carnitine chloride
(PCC), mg (%)

0.00 (0)

1.00 (2.0)

0.50 (1.0)

4.00 (8.0)

29.25
(58.5)

8.00
(16.0)

R5

0.00 (0)

1.00 (2.0)

0.50 (1.0)

4.02 (8.0)

36.00
(72.0)

8.00
(16.0)

R4

Sodium dodecyl sulfate
(SDS), mg (%)

0.50 (1.0)

0.50 (1.0)
1.00 (2.0)

4.05 (8.1)

4.15 (8.3)

36.22
(72.45)

8.00
(16.0)

R3

0.00 (0)

36.45
(72.9)

8.00
(16.0)

8 .00
(16.0)
37.35
(74.7)

R2

R1

AS FDSTs Formulations

Sodium bicarbonate, mg
(%)

Microcrystalline cellulose
(Ceolus® UF-702), mg (%)
Low-substituted
hydroxypropyl cellulose
(LH-11®), mg (%)
Magnesium stearate, mg
(%)

Atropine sulfate, mg (%)

Ingredients

Table II. Composition of AS FDST Formulations
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Evaluation of The Physical Characteristics and Quality Control Testing of AS
FDST Formulations

The mixed powder from each batch was tested for its flowability (PF) and moisture
content (MC) before compression. Then, the manufactured tablets were tested for their
breaking force (BF), friability (F), and content uniformity (CU) using the United States
Pharmacopeia (USP) standard tests and limits. Due to the lack of an accurate USP test that
can discriminate small differences between FDSTs, tablets’ disintegration time (DT) and
drug dissolution (DD) were tested using the previously developed and published
apparatuses and procedures that can detect small differences between tablets (Aodah et al.,
2017; Rachid et al., 2011). FDSTs’ wetting time (WT) and water uptake (WU) were tested
as well using modified procedures.

Powder flowability (PF) or the angle of repose test

Powder’s flow behavior is an important factor that has a significant impact on tablets
manufacturability (Prescott & Barnum, 2000). Powder flowability has a direct effect on
weight variability and content uniformity. A poor powder flowability results in huge weight
and content variation (Prescott & Barnum, 2000). Therefore, the flowability of the powder
mixture of each batch was tested before compressing the tablets. The mixed powder from
each formulation was poured into a clean funnel with a diameter of 7 cm at a height of 30
cm and allowed to freely flow on a flat stainless steel surface and form a cone shape. This
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process was repeated three times (n=3). The angle of repose was determined by using a
special protractor to measure the angle between the wall of the cone side and the flat surface
(Figure 10) (USP/NF, 2018d).
The USP powder flow properties and its corresponding angles of repose are presented
in Table III. The lower the angle of repose, the better the powder flowability (USP/NF,
2018d).

Figure 10. Measurement of the powder’s angle of repose using a goniometer angle finder,
miter gauge arm, measuring ruler protractor.
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Table III. Flow properties and corresponding angles of repose according to USP
(USP/NF, 2018d)

Flow Property

Angle of Repose (degree)

Excellent
Good
Fair—aid not needed
Passable—may hang up
Poor—must agitate, vibrate
Very poor
Very, very poor

25–30
31–35
36–40
41–45
46–55
56–65
>66

Moisture content (MC) test

Measuring the MC of the mixed powder is one of the important tests that can affect
drug stability and powder flowability. High percentage of powder MC indicates
difficulties, especially for FDST formulations due to increasing the ability to uptake
moisture from the surrounding which may negatively affects the tablet’s disintegration
(Alyami et al., 2017). A specific amount of the mixed powder from each formulation,
usually 1 g (n=3), was spread on the heating pan of a Halogen Moisture Analyzer HE73,
METTLER

TOLEDO® (Sonnenbergstrasse,

Schwerzenbach,

Switzerland).

The

temperature in the analyzer reached 300°C to evaporate all the moisture in the powder. The
MC (%) of the powder was recorded after heating based on the weight of powder used. The
powder samples were discarded after testing.
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Measurement of tablet’s dimensions

The tablet dimensions were measured to ensure the uniformity of the tablets
dimension and manufacturing. In this test, ten tablets were randomly selected from each
formulation and the diameter (D) and thickness at the tablet’s center (TC), were measured
using a digital caliber (VWR, Randor, PA) (Figure 11). The mean (± SD) was calculated
and recorded.

Figure 11. Measurement of the tablet’s dimensions using a digital caliber.
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Breaking force (BF) test

Breaking force “hardness” test was performed to test the amount of force required to
break up the tablet. It is critical to form hard FDSTs during manufacturing that pass the
friability test but without retarding the tablet’s disintegration. The test was performed
according to the USP guideline (USP/NF, 2018f). The BF of six randomly selected tablets
was measured using Vanguard Hardness Tester LIH-3 (Vanguard Pharmaceutical
Machinery, INC, Spring, TX). The mean (± SD) was calculated and recorded.

Friability (F) test

The friability (F) test is a required test according to the USP guidelines to ensure that
manufactured tablets can stand shipping and handling. The test involved testing 130
dedusted tablets equivalent to 6.5g using a USP friability tester (Vanguard Pharmaceutical
Machinery, INC, Spring, TX). Tablets were weighed before the test and then placed in the
drum and rotated for 100 rounds at 25 rpm. At the end of the test, the tablets were dedusted
and weighed again. The percentage of weight loss was calculated using the following
equation:
Weight Loss %=

(#$%&'( *$+,-$ – #$%&'( /+($-)
#$%&'( *$+,-$

X 100

The maximum allowed weight loss according to the USP criteria is less than or equal
to 1.0% (USP/NF, 2018e).
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Content uniformity (CU) test

Content uniformity is a quality control test used to assess the individual content of the
active ingredient in each tablet (Vranić & Uzunović, 2008). According to USP, content
uniformity test is required for tablets that contain less than 25 mg or less than 25% of the
active ingredient. Tablet content was analyzed by randomly selecting 10 tablets and
dissolving each one in 10 mL of distilled water by vortexing for 1 min. Aliquot sample
from each solution was collected, diluted, and then filtrated using 0.45 µm nylon syringe
filters (VWR, Randor, PA). Samples were analyzed by HPLC with UV detection (Waters
Corporation, Milford, MA) using the standard USP procedure for analyzing AS injection
(USP/NF, 2018g). The USP acceptance value (AV) of L1 (15% or less) was calculated for
each formulation (USP/NF, 2018c).

Tablet’s disintegration time (DT) test

Disintegration time test is an important test for ODTs and used to assess the time the
tablet takes to liberate its active ingredients to be available for absorption (Al-Gousous &
Langguth, 2015). An alternative non-USP disintegration test method was previously
developed and published for FDSTs (Aodah et al., 2017). The developed apparatus
included a rotating shaft (8 ± 2 mm diameter, 220 ± 20 mm height), a stainless-steel round
USP basket (38.5 ± 1 mm diameter, 23 ± 2 mm height) with a stainless-steel wire screen
(0.36 - 0.44 mm apertures and 0.22 - 0.31 mm wire diameter) attached at the base of the
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rotating shaft, and a glass beaker (30 ± 10 mm diameter, 40 ± 10 mm height, 20 mL
volume).
The test was performed by partially immersing the rotating basket that contains one tablet
rotated at a speed of 60 rpm into the glass beaker containing 2 mL of warmed water to 37
± 2 ºC to facilitate tablet disintegration. The time (in seconds) required for each tablet
(n=6) to disintegrate completely and for the fine particles to pass through the basket
screen into the beaker was determined using a stopwatch (Aodah et al., 2017) (Figure
12).

(b)

(a)

USP Basket
Rotating Shaft

AS FDST

USP Basket
Water (2 mL)
Glass Beaker
(20 mL)

Figure 12. (a) Disintegration apparatus; (b) USP stainless-steel basket.
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Drug dissolution (DD) test

Drug dissolution is critical and can be the rate limiting step for its absorption. Dissolution
test is a quality control test that can determine the extent and the rate of the drug
absorption (Kraemer, Gajendran, Guillot, Schichtel, & Tuereli, 2012). Dissolution test
was measured according to our previously developed and validated non-USP dissolution
test designed to simulate the low fluid volume and static environment available in mouth
cavity and to discriminate between small differences in the dissolution of different AS
FDST formulations (Rachid et al., 2011).
Tablets were randomly selected (n=6) and tested according to our previously published
procedure. Each tablet was dropped into the donor chamber that contained 2 mL of water
and connected to a sampling tube under vacuum. The donor chamber and the sampling
tub were separated by 0.45 µm filter membrane (Figure 13). After 60 sec, the vacuum
valve was activated and only the drug released and dissolved from each tablet was sucked
into the receiving sampling tube through the filter membrane, while the undissolved drug
and excipients were retained on the membrane (Rachid et al., 2011). Collected samples
were diluted and analyzed by HPLC with UV detection (Waters Corporation, Milford,
MA) using the standard USP procedure for analyzing AS injection to quantify and
calculate the percentage of AS dissolved from the tablet within 60 sec (USP/NF, 2018g).
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(a)

(b)
Donor Chamber
(2 mL Water)
Sampling
Tube

Vacuum
Line

Donor Chamber

Sampling Tube

Filter Membrane

Figure 13. (a) An illustrative dissolution apparatus (b) Disassembled dissolution
apparatus.
Water uptake (WU) test

For FDSTs, it is important to determine how well the tablet can absorb and hold water to
facilitate drug dissolution. In this non-USP test developed by Aodah and coworkers
(Aodah et al., 2017), the dry weight of each tablet (n=6) was measured using an
analytical balance (d=0.01 mg). Then, while the tablet was still on the balance, water was
added dropwise on the top of the tablet. Once the tablet could not hold more water and
water started to ooze out, its wet weight was recorded (Figure 14). The percentage of how
much the tablet can absorb and hold water was calculated using the following equation:
Water Uptake (%) =

(456 457896:;<= 457896)
;<= 457896

> 100
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Figure 14. Measurement of AS FDST’s water uptake.

Wetting time (WT) test

Similar to the dissolution test, wetting time was necessary to measure how fast water can
diffuse throughout the tablet to dissolve the drug and, therefore, measure small
differences in FDST formulations using a previously published non-USP method (Aodah
et al., 2017). Wetting time was recorded using a stopwatch right after placing each tablet
(n=6) on a wetted but drained paper towel to remove excess water before each test. The
time was recorded when the water penetrated throughout the entire tablet (Figure 15).
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A
B

Figure 15. Wetting time test of FDSTs.
A: an image for AS 50 mg FDST when placed on a wet paper towel at t0; B: an image of
FDST placed on a wet paper towel at the end of wetting test.

Ex vivo Permeability Studies

The ex vivo permeation of AS from each FDSTs formulation batch was performed to
evaluate and measure the sublingual permeability of AS, and the effect of various
excipients incorporated into the tablet formulation to optimize tablets’ physical
characteristics and AS sublingual permeability.

Franz cells preparation

Static vertical jacketed Franz cells containing donor and receiver chambers with an OD
of 20 mm, a reservoir volume of 20 ± 1 mL, and a magnetic stirrer at the bottom of the
receiver chamber (PermeGear Inc., Hellertown, PA) were used to perform the ex vivo
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permeability studies (Figure 16). The temperature of the circulating water was set at 37°C
± 1°C. The surgically excised thin sublingual epithelial membrane from the underlying
connective and fat tissues of a porcine lower jaw was used as the diffusional membrane
(n=4) as previously established and reported (Rachid et al., 2011; M. M. Rawas-Qalaji,
Werdy, Rachid, Simons, & Simons, 2015) (Figure 17). The integrity of the membranes
were visually examined and experimentally assessed for any significant variability in AS
permeability within each study. The excised membranes were stored at -20°C in phosphate
buffer, pH 6.8, which represent the average pH of the saliva (pH 5.8 – 7.5), until being
used within three months of their storage (Zhang, Zhang, & Streisand, 2002).
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Figure 16. An illustrative scheme for a Franz cell.

Figure 17. An image of excised porcine sublingual membrane.
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Evaluation of the effect of MCC filler grade on the sublingual permeability of AS
FDSTs formulation

For each study, excised sublingual porcine membranes were thawed at room
temperature and mounted on Franz cells for 30 min to equilibrate with the diffusion
medium from both sides. Air bubbles were removed from the receptor chambers and cells
were checked for leaks. The water bath was set at 37oC and water was circulated in the
jacketed Franz cells. A receiver chamber with a magnetic stirrer was filled with phosphate
buffer, pH 7.4 (which represent the pH of the blood). Deionized water 2 mL was used in
the donor chamber to facilitate tablet disintegration and dissolution. Tablets from FDSTs
formulation containing MCC UF-702 (formulation R1) (n=4) were placed at the center of
the mounted sublingual membrane in the donor chamber at time 0 (T0). Aliquots, 200 µL,
were withdrawn from the receptor chamber using of 22 G and 6 inches needles (Cadence
Inc., Cranston, RI) and 1 mL syringes at several time intervals, 5, 10, 15, 20, 30, 45, 60,
75, and 90 min. The volumes withdrawn were replenished with fresh phosphate buffer.
Samples were filtered and transferred into HPLC vials for HPLC analysis using UV
detector (Waters Corporation, Milford, MA) according to the standard USP method for
analyzing AS injection (USP/NF, 2018g).
The result was then compared to the previously prepared and published AS FDSTs
formulation (formulation B), that contained MCC PH-301 (Aodah et al., 2017).
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Evaluation of the ex vivo pH-permeability profile of AS FDSTs formulation

The ex vivo permeability of the AS FDSTs formulation using MCC UF-702
(formulation R1) was prepared and performed as described in section 3.5.2. However,
instead of using water in the donor chamber as a diffusion medium, Mcvilian buffer
(phosphate acetate buffer) was prepared at pH 5, 6.5, 6.8, or 8 and 2 mL of the prepared
buffer was placed in the donor chamber to establish a pH-permeability profile for AS and
to allow for tablet disintegration and AS dissolution.
The pH that facilitated the highest AS permeability from FDSTs was selected as the
optimal pH for AS sublingual permeability.

Evaluation of the effect of different pH-modifiers on the pH of AS solution

Three pH-modifiers were selected: Na Bicarb, Ca Carb, and Na Cit, used in two
concentrations (1 or 2% of tablet weight, 50 mg) to evaluate in vitro their ability to modify
the pH of deionized water as a diffusion medium, which has almost the same pH of human
saliva. Various concentrations from each pH-modifier were dissolved in 2 mL of deionized
water (n=3) and the pH of the solution was measured using a pH meter (Orion Star®,
Thermo Scientific, Waltham, MA). The pH-modifier that was able to modify the pH of the
diffusion medium to the optimal pH for AS sublingual permeation based on the ex vivo
pH-permeability studies (section 3.5.3) was then tested again with the addition of AS FDST
in 2 mL of deionized water to evaluate their effect along with AS in FDSTs.
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Evaluation of the effect of incorporating a pH-modifier and/or penetration
enhancers on the sublingual permeability of AS FDST formulations

Different AS FDST formulations containing a pH-modifier and/or a penetration
enhancer (Table II) were formulated and manufactured according to section 3.3 and
evaluated according to section 3.4. The ex vivo permeability of AS from these different AS
FDST formulations was performed as described in section 3.5.2. A 2 mL of deionized water
was used in the donor chamber to facilitate tablet disintegration and dissolution. AS FDSTs
permeated at pH 6.8 medium, the average saliva pH, was used as a control to evaluate the
effect of incorporating a pH-modifier and/or various penetration enhancers on AS
sublingual permeability.

Statistical Analysis

The mean (± SD) of the results from the physical tests including, PF, MC, BF, F, CU,
DT, DD, WU, and WT for each FDSTs formulation were calculated AS FDSTs
formulation without pH-modifier and penetration enhancers were statistically compared to
the previously prepared and published AS FDSTs formulation (formulation B) (Aodah et
al., 2017) using student’s t-tests. Al the rest of AS FDST formulations prepared in this
project were statistically compared within each other by a one-way analysis of variance
(ANOVA) and Tukey-Kramer tests.
The mean (± SD) of cumulative amount of AS (µg/cm2) permeated over time was
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plotted and the area under the curve of AS permeated for 90 min (AUC0–90) and 15 min
(AUC0–15) were calculated for each AS FDST formulation. The mean of AS influx, J
(µg/cm2.min), was determined from the slope of the linear portion of the amount of drug
permeated versus time curve. The AS permeability coefficient, P (cm/min), was calculated
by dividing J by the initial AS concentration in the donor chamber at T0, which is 8 mg in
2 mL (4 mg/mL). The Lag time (LagT), which is the time required for AS before it started
to diffuse through the sublingual membrane to the receiving chamber, was calculated by
extra-plotting the slope line to intersect with the X-axis. Data were statistically compared
by student’s t-tests or one-way ANOVA and Tukey-Kramer tests.
All the statistical analysis tests were performed using NCSS statistical software (NCSS,
Kaysville, UT). Differences were considered to be statistically significant at p<0.05.

Chapter Summary

In this chapter, the methods and the designs of the studies performed in order to achieve
the objectives of this project were discussed in detail. Ten different formulations of AS
FDSTs weighing 50 mg were prepared and manufactured using a new filler grade (UF702), a pH-modifier (Na Bicarb), and/or a penetration enhancers (SDS, PCC, or Na Gly).
Each formulation was evaluated for its physical characteristics. The PF, MC, CU, and F
tests were performed and evaluated using the USP standard tests. However, due to lack of
an accurate USP testing method that can discriminate small differences between FDSTs,
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DT, DD, WT, and WU tests were performed using our developed apparatuses and
procedures to detect small differences between tablets.
Testing AS permeability at a range of pH values to evaluate the pH-permeability profile
of AS sublingual tablets were used as a guideline for choosing the optimal pH and pHmodifier to be incorporated into the tablet’s formulation. In order to evaluate the AS
sublingual permeation and the effect of incorporating a pH-modifier and/or a penetration
enhancer into the tablet formulation, various ex vivo permeation studies were performed
for each formulation using static vertical jacketed Franz cells. All the results and data from
the quality control tests as well as the ex vivo permeation studies were analyzed using
HPLC system with a UV detector and statistically analyzed.
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Results

Chapter Overview

In this chapter, the results for the described studies in the methods section were
presented in detail. These include the results from HPLC qualification method tests, quality
control and physical tests for AS FDST formulations, AS permeability studies to establish
the pH-permeability profile, the pH results from using different pH-modifiers, and results
from evaluating the effect of a pH-modifier and or various penetration enhancers on
enhancing AS sublingual permeability from various AS FDST formulations. In this
chapter, the most significant results were illustrated and emphasized using tables and
figures to easily compare the results for the different FDST formulations. Mean ± SD was
calculated and compared by T-test, one-way ANOVA and Tukey-Kramer tests using NCSS
statistical software (NCSS, Kaysville, UT). Differences were considered to be statistically
significant at p< 0.05.
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HPLC Method Qualification

Atropine sulfate calibration curves

Calibration curves ranging from 5 to 200 µg/mL (n=5) were linear with a correlation of
coefficient (R2) of > 0.9998. The retention time of AS was at 8 min. The mean of the
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Figure 18. AS calibration curves (n=5).
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Instrument and method reproducibility

The HPLC system reproducibility was evaluated by analyzing the lowest and highest
concentrations of AS (n=5), 20 µg/mL and 200 µg/mL. The RSD% for the injected
concentrations were 0.7% and 0.2%, respectively.

Injection volume accuracy

The instrument accuracy was evaluated by injecting 20 µg/mL AS standard, using
increasing injection volumes starting from 10 µL. The AUC of the injected volumes
(n=6) resulted a linear correlation with a correlation of coefficient of R2= 0.999 (Figure
19).

AUC (Absorbance nm (UV.Sec)

Thousands

89
20
18
R² = 0.9999

16
14
12
10
8
6
4
2
0
0

10

20

30

40

50

60

70

80

90

100

110

Injection Volume (µL)
Figure 19. The linearity of the autosampler’s injection volume.

Intra and inter-assay variation system

The RSD% for the intra and inter-assay (n=3) of different AS concentrations were
calculated and the results were shown in Table IV.
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Table IV. Intra and inter-assay variation
AS Concentration (µg\ml)
RSD%
5

10

20

40

80

160

200

Intra-assay

0.5

0.5

0.9

0.6

0.9

0.9

0.4

Inter-assay

0.4

0.4

0.9

0.2

0.3

0.8

0.2

RSD%: relative standard deviation percentage.

The limit of quantification

The minimum amount of AS that could be detected and quantified using the HPLCUV detector system was 125 ng with an RSD% of 1.6% (n=5).

Physical Characteristics and Quality Control Testing of AS FDST Formulations

The effect of the MCC filler grade on the physical characteristics of AS FDSTs
formulation

The current new formulation of AS FDSTs (formulation R1), that contained MCC UF702, was evaluated based on the various previously described physical tests in section 3.4
and was compared to the previously prepared and published AS FDSTs formulation
(formulation B) (Aodah et al., 2017). Results comparing the physical characteristics of the
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new AS FDSTs formulation containing MCC UF-702 to the previously developed and
published AS FDSTs formulation containing MCC PH-301 were summarized in Table V.
Mean (± SD) angle of repose of the powder mixture for formulation R1 was 32° ± 0.5°,
which was significantly lower (p<0.05) than formulation B, 42° ± 2°. The tablet BF of
formulation B (1.9 ± 0.6 kgf) was significantly lower (p<0.05) than formulation R1 (2.5 ±
0.1 kgf). AS FDSTs from formulation R1 had significantly faster DT (p<0.05), higher WU
and DD compared to AS FDSTs from formulations B (Table V). However, the WT was
significantly (p<0.05) faster in formulation B AS FDSTs compared to formulation R1 AS
FDSTs.

Table V. Quality control tests of atropine sulfate 8 mg FDST formulations
Test

AS FDST Formulations
B

R1

42 ± 2

32 ± 0.5*

1.9 ± 0.6

2.5 ± 0.1*

0.09

0.05

Disintegration Time (sec)

14.0 ± 0.4

5.0 ± 0.6*

Drug Dissolution (%)

88.5 ± 14

99.5 ± 6.2*

Water Uptake (%)

229 ± 12

303 ± 16*

Wetting Time (sec)

11 ± 1

17.0 ± 0.9*

Powder Flow (repose angle)
Breaking Force (kgf)
Friability (loss %)

Results were presented as mean (± SD)
B: AS FDSTs using MCC PH-301; R1: AS FDSTs using MCC UF-702.
*
p<0.05
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Powder flowability (PF) or angle of repose test

According to the USP criteria (USP/NF, 2018d), all the powder blends developed for
AS FDST formulations in this project had either a passable or a good angle of repose based
on Table III. The angle of repose results for the powder blends from the different
formulations were presented in Table VI.

Moisture content (MC) test

Moisture content was tested for all the powder blends from the different AS FDST
formulations. MC can influence the tablets stability and powder flowability. The addition
of the pH-modifier and/or transcellular penetration enhancers (formulation R2, R3, R4, R6,
R7, R8, R9, and R10) showed a significantly higher (p<0.05) MC than AS FDSTs
formulation with no pH-modifier and/or penetration enhancers (formulation R1). However,
the difference was higher when the transcellular enhancers were added alone to AS FDSTs
(formulation R8, R9, R10). The results of MC from the different AS FDST formulations
were presented in Table VI.

Tablets’ dimensions measurement

All the tablets prepared for the different formulations of AS FDSTs had the same
tablet’s size. The mean (± SD) of tablet’s dimensions including, tablet’s diameter and
tablet’s central thickness for different AS FDST formulations were shown in Table VI.
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Breaking force (BF) test

At the same compression force used (130 – 150 kgf), different formulations showed
different tablets’ hardness. Breaking force of the manufactured tablets ranged from 2.0 to
2.4 kgf. However, these differences between the different AS FDST formulations were not
significantly different (p>0.05). The tablet hardness results for each AS FDSTs formulation
were presented in Table VI.

Friability (F) test

According to the USP, the maximum weight loss allowed for a tablet dosage form is
no more than 1% (USP/NF, 2018e). All the manufactured AS FDST formulations passed
the friability test. The friability results for each AS FDSTs formulation were shown in
Table VI.

Content uniformity (CU) test

According to the USP criteria for dosage form’s content uniformity (USP/NF, 2016),
all AS FDST formulations passed the acceptance value (AV) for CU, with AV of ≤ 15. The
mean (± SD) of tablets’ CU% and AV for each FDSTs formulation were presented in Table
VI.
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Tablet’s disintegration time (DT) test

The addition of the pH-modifier (Na Bicarb) and/or penetration enhancers (SDS, PCC,
Na Gly) significantly increased (p<0.05) the tablet’s disintegration time compared to the
AS FDSTs formulation with no pH-modifier and/or penetration enhancers (formulation
R1). Despite the addition of the pH-modifier and/or the penetration enhancers into the
tablet formulations containing the new MCC filler grade UF-702, most of the AS FDST
formulations (formulation R2, R3, R4, R6, R7, R8, and R10) had a short disintegration
time of less than 12 sec. AS FDST formulations containing the paracellular enhancer PCC
16% with or without a pH-modifier (formulation R5 and R9) resulted in the longest
disintegration time (p<0.05) of 12 sec and 16 sec, respectively. All the disintegration results
for the different AS FDST formulations were shown in Table VI.

Drug dissolution (DD) test

The percentage of dissolved AS from AS FDSTs in the first 60 seconds for all the AS
FDST formulations were almost complete. The addition of the pH-modifier and/or
penetration enhancers (formulation R2, R3, R4, R6, R7, R8, and R10) showed no negative
effect (p>0.05) on the percentage of AS dissolved per minute. The addition of the 16%
paracellular enhancer PCC with or without a pH-modifier (formulation R5 & R9) resulted
in significantly less (p<0.05) AS percentage dissolved per min (86% and 88) compared to
the other formulations. The mean (± SD) of DD% for all AS FDST formulations were
shown in Table VI.
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Water uptake (WU) test

The WU by the AS FDSTs formulation with no pH-modifier and/or penetration
enhancers (Formulation R1) was significantly higher (p<0.05) than the formulations that
had a pH-modifier, a pH-modifier with or without penetration enhancers, and penetration
enhancers alone (formulation R2, R3, R4, R5, R6, R7, R8, R9, and R10). Also, the addition
of the transcellular enhancer Na Gly 20% with or without the pH-modifier resulted in the
lowest (p<0.05) percentage of WU (247% and 240%). The mean (± SD) percentage of
tablet’s WU for all AS FDST formulations were shown in Table VI.

Wetting time (WT) test

The WT of FDSTs was only affected by the addition of the penetration enhancers alone
without the pH-modifier including, SDS 1% (formulation R8), PCC 16% (formulation R9),
and Na Gly 20% (formulation R10). They all significantly increased (p<0.05) the tablet’s
WT compared to the other AS FDST formulations (Table VI). Also, AS FDSTs
formulation with the pH-modifier and paracellular enhancer PCC 16% (formulation R5)
resulted in the longest WT (P<0.05) compared to the all other formulations. The WT results
for all AS FDST formulations were shown in Table VI.

4.8±0.0

Diameter

99.5±6.2

Drug Dissolution (%)

17.0±1.1

281.0±8.4

100.0±1.4

9.0±0.0

106.0±2.2
(9.8)

0.02±0.0

2.4±0.2

17.0±1.2

281.0±3.6

106.0±5.3

7.0±1.0

95.3±2.2
(8.4)

0.02±0.0

2.3±0.2

4.8±0.0

3.1±0.0

8.0±0.0#

33.0±0.6

R3

10.0±0.6*

285.0±3.8

96.6±6.0

8.0±1.0

107.6±0.4
(7.2)

0.04±0.0

2.1±0.2

4.8±0.0

3.1±0.1

8.0±0.0#

33.0±1.1

R4

35.0±0.9*

276.0±12.3

86.4±8.2$

12.0±1.1*

98.3±3.4
(8.4)

0.4±0.0

2.0±0.1

4.8±0.0

3.1±0.05

7.0±0.0

34.0±0.0

R5

13.0±1.2*

274.0±6.0

90.0±9.7

9.0±0.0

95.2±4.3
(13.7)

0.02±0.0

2.1±0.2

4.8±0.0

3.1±0.0

9.0±0.0#

35.0±0.6

R6

FDSTs Formulations

19.0±0.8

247.0±9.8$

107.0±6.3

10.0±0.6

111.4±1.0
(12.3)

0.05±0.0

2.0±0.9

4.8±0.0

3.1±0.0

9.0±0.0#

37.0±0.6

R7

38.0±1.0$

284.0±6.5

93.0±6.0

10.0±0.6

109.7±1.9
(12.7)

0.09±0.0

2.2±0.3

4.8±0.0

3.1±0.0

15.0±0.0$

36.0±0.6

R8

40.6±0.7$

274.0±3.0

88.0 ±4.1$

16.0±0.5*

105.2±3.6
(11.2)

0.06±0.0

2.4±0.4

4.8±0.0

3.1±0.02

14.0±0.0$

36.0±1.1

R9

38.0±2.2$

240.0±9.7$

91.1±4.8

7.0±0.0

97.1±2.2
(6.7)

0.08±0.0

2.0±0.2

4.8±0.0

3.1±0.0

12.0±0.0$

35.0±0.0

R10

Results were presented as mean (± SD)
R1: AS FDSTs using MCC UF-702; R2: AS FDSTs with Na Bicarb 2%; R3: AS FDSTs with Na Bicarb 2% and SDS 0.5%;
R4: AS FDSTs with Na Bicarb 2% and SDS 1%; R5: AS FDSTs with Na Bicarb 2% and PCC 16%; R6: AS FDSTs with Na
Bicarb 2% and Na Gly 15%; R7: AS FDSTs with Na Bicarb 2% and Na Gly 20%; R8: AS FDSTs with SDS 1%; R9: AS FDSTs
with PCC 16%; R10: AS FDSTs with Na Gly 20%.
*
p<0.05 from all.
$
p<0.05 from all but not than each other.
#
p<0.05 from AS FDSTs using MCC UF-702 (R1), i.e. AS FDSTs without a pH-modifier and penetration enhancers.

17.0±0.9

5.0±0.6*

Disintegration Time (sec)

Wetting Time (sec)

102.8±3.7
(10.3)

Content Uniformity (%)
(AV)

303.0±16.4*

0.05±0.0

Friability (loss%)

Water Uptake (%)

2.4±0.1

Breaking Force (kgf)

4.8±0.0

3.1±0.0

3.15±0.07

Thickness

Tablet
Dimensions

9.0±0.0#

7.0±0.0

Moisture content (%)

35.0±0.0

R2

32.0±0.6

R1

Powder Flowability (angle)

Test

Table VI. Quality control tests of AS FDST formulations
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Ex Vivo Permeability Studies

The effect of the MCC filler grade on the sublingual permeability of AS FDSTs
formulation

The mean (± SD) cumulative amount of AS permeated over time from both formulations,
the previously developed AS FDSTs formulation (Formulation B) and the current
formulation (Formulation R1) were plotted in
Figure 20. Formulation R1 AS FDSTs resulted in a significantly higher (p<0.05) mean
(± SD) cumulative amount of AS permeated (AUC) over 90 and 15 min, AS influx, and
significantly decreased the permeation lag time in comparison to formulation B AS FDSTs
(Table VII).
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Figure 20. The cumulative AS permeated per area (µg/cm2) versus time from FDST using
MCC PH-301 (formulations B) and UF-702 (Formulation R1).
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Table VII. Ex vivo permeability of atropine sulfate 8 mg FDST formulations in water as a
diffusion medium
AS FDSTs Formulations
B

R1

Area under the curve,
AUC0-90 min (µg/cm2/min)

14995 ± 3184

23239 ± 550*

Area under the curve,
AUC0-15 min (µg/cm2/min)

122 ± 150

722 ± 134*

Influx, J (µg/cm2/min)

4.6 ± 0.9

7.7 ± 0.8*

Lag time, LagT (min)

11.2 ± 4.7

0.0 ± 0.0*

Results were presented as mean (± SD)
B: AS FDSTs using MCC PH-301; R1: AS FDSTs using MCC UF-702.
*
p<0.05.

The ex vivo pH-permeability profile of AS FDSTs formulation

The mean (± SD) cumulative amount of AS permeated over time from AS FDSTs at
various pH media were plotted in
Figure 21. During the first 20 min of the permeation studies, AS permeation from
formulation R1 AS FDSTs at different pH media did not show any significant difference
(p>0.05). However, the mean (± SD) of AUC0-90 of AS permeated, J, and P from
formulation R1 AS FDST in a diffusion medium of pH 8 were statistically higher (p<0.05)
than at all other pH media (5, 6.5 and 6.8). Also, the AUC, J, and P from formulation R1
AS FDST at pH 6.8 medium, which represented the average saliva pH, were statistically
higher (p<0.05) than at pH 5 medium (Table VIII).
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Figure 21. The cumulative AS permeated per area (µg/cm2) versus time from FDSTs
formulation R1 at different pH medium

Table VIII. Ex vivo permeability of AS FDSTs at different pH

AS FDSTs Formulation (R1) at Different pH
Medium
pH 5

pH 6.5

pH 6.8
(control)

pH 8

9708 ± 13530

9908 ± 14330

11232 ±
12006

22715 ± 524*

3.0 ± 0.5

3.3 ± 0.3

4.5 ± 0.4$

8.4 ± 1.6*

Permeability coefficient,
6.0x10-4 ±
1.2x10-4
P (cm/min)
Results were presented as mean (± SD)
*
p<0.05 from all.
$
p<0.05 from pH 5.

8.2x10-4 ±
8.6x10-5

1.1x10-3 ±
9.7x10-5 $

2.1x10-3 ±
4.1x10-4*

Area under the curve,
AUC0-90 min (µg/cm2/min)
Influx, J (µg/cm2/min)
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The effect of different pH-modifiers on the pH of AS solution

Na Bicarb 2% resulted in a pH of 8.1 ± 0.3 that was significantly higher (p<0.05) than all
other buffers at the various concentrations used. Also, incorporating Na Bicarb 2% into
AS FDSTs formulation resulted in a similar (p>0.05) pH value of 7.9 ± 0.1. The mean (±
SD) pH values for the different buffers used at different concentration were shown in
Table IX.
Table IX

Concentration
Concentration
(%) (%)

pH-Modifiers
Na Bicarb

Ca Carb

Na Cit

1%

7.2 ± 0.2

6.6 ± 0.1

6.2 ±0.3

2%

8.1 ± 0.3*

7.6 ± 0.1

7.5 ± 0.1

7.9 ± 0.1
2% with AS FDSTs
Table IX. pH measurements of different pH-modifiers at different concentrations

Results were presented as mean (± SD)
*
p<0.05 from all except 2% Na Bicarbonate incorporated into AS FDSTs.

The effect of incorporating a pH-modifier with or without penetration enhancers on
the sublingual permeability of AS FDST formulations

The mean (± SD) cumulative amount of AS permeated over time from AS FDSTs that
contained the pH-modifier (2% Na Bicarb) with or without penetration enhancers (SDS,
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PCC, or Na Gly at different concentrations) were plotted in Figure 22. The mean (± SD)
AUC0-90 of cumulative drug permeated, J, and P from AS FDST formulations (formulation
R2, R3, R4, R5, R6, and R7) were statistically higher (p<0.05) than the control
(formulation R1 at pH 6.8) (Table X). The mean (± SD) AUC0-90 of cumulative AS
permeated, J, and P from AS FDSTs with the pH-modifier and transcellular enhancers
(formulation R3, R4, R6, and R7) were significantly higher (p<0.05) than with the
paracellular enhancer (formulation R5) and the control (Table X). Incorporating the pHmodifier Na Bicarb 2% with SDS 1% (formulation R4) achieved the highest enhancement
in AS sublingual permeability (p<0.05) and increased AS permeability 13-fold compared
to the control. The ex vivo results for the different AS FDST formulations were shown in
Table X.
Also, the J and P of AS FDST formulations with the pH-modifier and paracellular
enhancers (formulation R5) showed similar results (p>0.05) compared to the AS FDST
formulations with the pH-modifier alone (formulation R2) (Table X).
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Figure 22. The cumulative AS permeated per area (µg/cm2) versus time from FDST
formulations with pH-modifier and penetration enhancers.
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Table X. Ex vivo permeability of different AS FDST formulations containing a pHmodifier and penetration enhancers
AS FDSTs Formulations
R1

R2

R3

R4

R5

R6

R7

11232 ±
12006*

30696 ±
510*

40173 ±
1396*

114334
± 3413*

25339 ±
1527*

79071 ±
1429*

84775 ±
908*

4.5 ±
0.4*

9.6 ±
1.6$

19.3 ±
1.0*

56.1 ±
4.3*

9.5 ±
2.0$

26.4 ±
0.5*

31.0 ±
0.2*

1.1x10-3
±
9.7x10-5*

2.4x10-3
±
4.0x10-4$

5.0x10-3
±
2.2x10-4*

1.4x10-2
±
1.1x10-3*

2.4x10-3
±
5.1x10-4$

6.6x10-3
±
1.2x10-4*

7.7x10-3
±
6.5x10-5*

(control)

Area under the curve,
AUC0-90 min (µg/cm2/min)
Influx, J (µg/cm2/min)
Permeability coefficient,
P (cm/min)

Results were presented as mean (± SD)
R1: AS FDSTs at pH 6.8 medium using MCC UF-702; R2: AS FDSTs with Na Bicarb 2%;
R3: AS FDSTs with Na Bicarb 2% and SDS 0.5%; R4: AS FDSTs with Na Bicarb 2% and
SDS 1%; R5: AS FDSTs with Na Bicarb 2% and PCC 16%; R6: AS FDSTs with Na Bicarb
2% and Na Gly 15%; R7: AS FDSTs with Na Bicarb 2% and Na Gly 20%.
*
p<0.05 from all.
$
p<0.05 from all but not each other.

The effect of incorporating penetration enhancers on the sublingual permeability of
AS FDST formulations

The mean (± SD) cumulative amount of AS permeated over time from AS FDSTs that
contained a penetration enhancer (SDS, PCC, or Na Gly) were plotted in Figure 23. The
mean (± SD) AUC0-90 of cumulative drug permeated and J from AS FDSTs with
transcellular enhancers (formulation R8 and R10) were significantly higher (p<0.05) than
AS FDSTs with paracellular enhancer (formulation R9) and the control (Table XI)
(Figure 23). Also, the P of AS FDSTs formulation with the transcellular enhancer (SDS)
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showed a significantly higher (p<0.05) result compared to the other enhancers and
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Figure 23. The cumulative AS permeated per area (µg/cm2) versus time from FDST
formulations with penetration enhancers.
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Table XI. Ex vivo permeability of different AS FDST formulations containing only
penetration enhancers
AS FDST Formulations
R8

R9

R10

Area under the curve,
AUC0-90 min (µg/cm2/min)

R1
(control)
11232 ±
12006*

27180 ±
2726$

22947 ±
1210*

28228 ±
1488$

Influx, J (µg/cm2/min)

4.5 ± 0.4*

8.5 ± 1.0$

3.0 ± 0.2*

6.0 ± 0.7$

Permeability coefficient,
1.1x10-3 ±
2.1x10-3 ±
8.0x10-4 ±
1.8x10-3 ±
P (cm/min)
9.7x10-5
2.6x10-4*
6.5x10-5
2.0x10-4
Results were presented as mean (± SD)
R1: AS FDSTs at pH 6.8 medium using MCC UF-702; R8: AS FDSTs with SDS 1%; R9:
AS FDSTs with PCC 16%; R10: AS FDSTs with Na Gly 20%.
*
p<0.05 from all.
$
p<0.05 from all but not each other.

Chapter Summary

In this chapter, AS calibration curves were successfully created using the standardized
USP analytical method. Both the analytical instrument and the quantification method
demonstrated high accuracy and reproducibility. All the physical characteristics and
quality control tests, USP and non-USP tests, for the different manufactured FDST
formulations were successfully performed. The results of the physical characteristic as well
as the ex vivo permeability test for the optimized AS FDST formulations using the new
MCC filler grade were reported and resulted in more optimal characteristics. The pHpermeability profile for AS was determined and the relationship between the medium’s pH
and AS sublingual permeation was established. The different AS FDST formulations
prepared with the addition of pH-modifier and/or penetration enhancers and their effect on
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AS sublingual permeability were also investigated and compared to the control to
demonstrate enhancement in AS sublingual permeation from the optimized AS FDSTs.
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Discussion

Overview

In this project, different ways and strategies for enhancing the physical characteristics
as well as the sublingual permeation and absorption of AS for a previously prepared AS
FDSTs (Aodah et al., 2017), were explored and evaluated. The tablets characteristics for
the sublingual delivery of AS for the treatment of OP toxicity is very critical since the tablet
should disintegrates rapidly to release the drug into the sublingual area. Also, complete and
rapid drug dissolution should be obtained in the small saliva volume to ensure rapid and
efficient drug absorption (Nayak & Manna, 2011; Wang & Chow, 2014; Washington &
Washington, 2001; Zhang et al., 2002).
The overall objective of this project is to develop a new dosage form for AS that can
overcome the many drawbacks associated with the use of current AS auto-injector,
AtroPen®. The proposed AS FDSTs, as alternative first-aid dosage form, should possess
the physical qualities that allow them to withstand the USP criteria and function to deliver
a bioequivalent dose of AS comparable to AtroPen® in order to attain a clinical
significance.
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In order to achieve this goal, optimizing the AS FDSTs formulation by changing the
MCC filler grade was one of our strategies to enhance the quality and the physical
characteristics of the tablet. The standard USP tests including, CU, F, and BF, and in-house
developed and modified tests including, DT, WT, WU, and DD, were used to evaluate the
effect of changing the filler grade on tablet characteristics and ensure the stringent criteria
for sublingual drug delivery are met.
In order to achieve optimal AS permeation and absorption, AS permeability at various
pH media was explored to evaluate the effect of altering the microenvironment’s pH of the
sublingual cavity and the potential of incorporating a pH-modifier into the tablet
formulation.
Additionally, the effect of various penetration enhancers at various concentrations on
AS sublingual permeability were also explored by incorporating various penetration
enhancers with or without a pH-modifier into the tablet formulation and evaluating their
effect on AS sublingual permeability in order to enhance AS sublingual permeability from
FDSTs.

The Effect of MCC Filler Grade on the Physical Characteristics and Sublingual
Permeability of AS FDSTs Formulation

Microcrystalline cellulose is a widely used filler that is manufactured by different
companies and available in various grades of different properties to be used in different
pharmaceutical formulations and dosage forms. Fillers with different properties can
perform differently when compared at discriminating conditions like the very strict
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conditions of the sublingual route and when the sublingual dosage form is subjected to lowvolume static conditions under the tongue that does not aid dosage form disintegration or
drug dissolution. MCC PH grade is one of the commonly used conventional grades in tablet
formulations and MCC UF grade is one of the more recent highly compressible grades
manufactured by Asahi Kasei Corp that were used in the formulation of our AS FDSTs. In
this project, changing the conventional MCC filler grade, PH-301, in formulation B to a
highly compressible MCC UF-702 grade in formulation R1 resulted in significant changes
in AS FDST’s physical characteristics and AS permeability.
MCC UF-702 grade is spherical in shape, has an average particles size of 90 µm, and
a repose angle of 34°. On the other hand, MCC PH-301 grade has an irregular particles’
shape, an average particles size of 50 µm, and a repose angle of 41° (Table I) (Asahi, 2018).
The particles size distribution, the shape, and the density of the filler’s particles are
important variables that can influence the entire powder flowability, since the filler
constitutes the majority of the tablet composition (Kucera, DiNunzio, Kaneko, &
McGinity, 2012). The larger particles size of MCC UF-702 grade provided a less frictional
contacting surface area between the MCC UF-702 particles and the surface they are
flowing against. Also, the spherical shape of MCC UF-702 particles facilitated a better
flow and resulted in a significantly lower angle of repose (32˚ ± 0.5˚) for formulation R1
powder mixture compared to the angle of repose (42˚ ± 2˚) for formulation B powder
mixture which contained MCC PH-301 that has irregularly particle shaped (Table V)
(Horio et al., 2014).
MCC UF-702 grade has a more porous structure as demonstrated by its lower bulk
density of 0.29 g/cm3 compared with a bulk density of 0.41 g/cm3 for MCC PH-301 grade
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(Table I) (Asahi, 2018). The porous structure of UF-702 grade can result in a higher plastic
deformation, which means better compatibility, and faster tablet disintegration compared
to PH-301 grade at similar compression forces (Dinunzio et al., 2012). It allows for better
and faster water penetration by capillary action through the pores, which promotes tablet
swelling and disintegration (Thoorens, Krier, Leclercq, Carlin, & Evrard, 2014). This
correlated well with the hardness and disintegration results from formulation R1 and
formulation B FDSTs. Harder tablets were obtained for formulation R1 FDSTs without
negatively affecting the tablet disintegration (Table V) despite being manufactured at
similar compression forces. The difference in the tablet porosity created due to using UF702 grade in formulation R1 FDSTs resulted in a harder tablet compact and faster tablet
disintegration compared to formulation B FDSTs. The disintegration time for AS FDSTs
was measured using our previously developed and published method that resembles the
statics and low solution volume conditions in the human mouth (Aodah et al., 2017). This
method was able to measure the time required in seconds for the AS FDSTs to disintegrate
into fine particles and to discriminate between different formulations (formulation R1 and
B FDSTs), which cannot be measured by the current official USP standard disintegration
test (Aodah et al., 2017; USP/NF, 2018a).
Tablet’s WT and WU measure the speed and extent of water absorption by the tablet
to initiate drug dissolution and disintegrate the tablet. The number of bonds formed
between the particles during compression is one of the variables that can affect tablet
porosity and excipients swelling extent, which affects the speed and extent of water
penetration into the tablet (Thoorens et al., 2014). Wetting test utilized a very small amount
of water just enough to wet the paper towel used in this test representing a stringent testing
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conditions, which can be correlated to a dry mouth clinical condition that can negatively
impact the tablet’s disintegration. Because formulation R1 FDSTs had a higher tablet
hardness, they showed a longer (p<0.05) wetting time compared to formulation B FDSTs
(Table V). It seems that the amount of water used in the wetting test may not have been
sufficient to overcome the stronger bonds formed within formulation R1 FDSTs, therefore,
significant wetting time difference was achieved. On the other hand, when more water was
presented in the disintegration and water uptake tests representing normal or excess
salivary secretions manifested in case of OP toxicity, tablet’s disintegration and water
uptake in formulation R1 FDSTs were significantly better (p<0.05) when compared to
formulation B FDSTs (Table V).
In order to confirm the significance of improving tablet characteristics (disintegration,
wetting, and water uptake) on the rate of drug dissolution, the amount of drug dissolved
within only 60 sec were measured using our previously validated and published apparatus
and method, since it cannot be measured by the current official USP standard dissolution
test (Aodah et al., 2017; USP/NF, 2018b). This apparatus and method were developed to
simulate the short time and static and low volume conditions available for drug
disintegration and dissolution following a sublingual drug administration (Aodah et al.,
2017; Rachid et al., 2011) The significant impact of changing MCC PH-301 grade to MCC
UF-702 grade was well demonstrated not only on the characteristics of FDSTs but also on
the rate AS dissolution (Table V). Formulation R1 FDSTs promoted complete AS
dissolution without any agitation within 60 sec (99.5 ± 6.2%) that was significantly higher
than formulation B FDSTs (88.5 ± 14%), an indication for the release of more amount of
AS from the tablet due to better AS FDSTs characteristics.
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These results can be very meaningful and critical when they are correlated with a
significant increase in sublingual AS permeation and absorption in order to demonstrate a
clinical significance. Therefore, the sublingual permeation of AS from these FDSTs were
evaluated through excised porcine sublingual membranes using Franz diffusion cells.
Replacing MCC PH-301 grade with MCC UF-702 grade resulted in a significant increase
in the overall AS permeation over time, AS influx, and reduced AS permeation lag time
(Table VII).
For the treatment of emergency conditions, the rate of drug absorption is as critical as
the amount of drug being absorbed in order to achieve the fast onset of action required for
treating these conditions. For this reason, the amount of drug diffused for 15 min, (AUC0–
15)

(µg/cm2) was also calculated for further analysis.
The lag time and the amount of AS permeated during the initial 10-20 min (Figure 20)

can be useful in guiding the AS FDSTs development. Changing the filler grade to UF-702
in formulation R1 FDSTs reduced the lag time from 11.2 ± 4.7 min to zero min and
increased the AUC0-15min almost 6-fold (Figure 20). The reduction in lag time was mainly
due to the significant increase in tablet disintegration and AS dissolution that permitted for
immediate and significantly higher AS permeation through the sublingual membrane.
Further drug absorption beyond the applicable time for sublingual absorption, although
increased the overall AS permeated over time, may have no clinical significance for the
treatment of emergency conditions that require fast onset of action during the short
administration time required for sublingual route. The delayed increase in the AS
permeated from formulation R1 FDSTs after 75 min of the permeability study (Figure 22)
was mainly due to the accumulation of AS in the donner cell that was able to overcome the
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permeability resistance of the sublingual membrane. The delayed increase in AS
permeation, despite of its clinical insignificance for the sublingual treatment of OP toxicity,
is another confirmation that formulation MCC UF-702 was superior to MCC PH-301 and
resulted in faster drug release, higher dissolution, higher concentration, and higher drug
permeation over time. A similar increasement were expected to be achieved by formulation
B FDSTs, despite of its insignificance, if permeability studies were extended beyond 90
min.
In summary, the results from this research support that the filler grade can play a critical
role in changing the characteristics of AS FDSTs, which can have significant implications
on the permeation and potentially the absorption of sublingually administered AS from
FDSTs formulation, and therefore, may increase the potential of developing an alternative
non-invasive dosage form for the treatment of OP toxicity.

The Ex Vivo pH-Permeability Profile of AS FDSTs Formulation

The permeability of any drug is known to be affected by three main factors. These
include charges, lipophilicity, and molecular weight of the drug molecules (Lee et al.,
2005). The extent of sublingual absorption of AS FDSTs can be greatly dependent on its
degree of ionization, which is mainly affected by the pH of the saliva. Therefore, the
evaluation of various pH medium is critical for enhancing AS sublingual permeability.
Mcvilian buffer was prepared at pH 5, 6.5, 6.8, and 8 to establish a pH-permeability profile
for AS FDSTs. The amount of AS permeated from FDSTs (formulation R1) at various pH
medium was measured. The results from this test were very important as to evaluate the
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effect of AS degree of ionization, as a result of changing the medium pH, on AS
permeability from FDSTs. Also, it guided the determination of the optimal pH for AS
sublingual permeability and, therefore, the criteria for the ideal pH-modifier that is needed
to be incorporated into AS FDSTs formulation to modify the sublingual microenvironment
pH to that optimal pH.
AS is a weak base with a pKa of 9.4 and a logP of 2.19 (NIH, 2018). This means that
at pH 9.4, 50% of the drug will be in the unionized form, which allow for better absorption
for the lipid soluble unionized portion of the drug through cell membrane (Lee et al., 2005).
The results from our Franz cells permeability studies indicated that the initial AS
permeated, due to the fast DT of the tablet and fast release and dissolution of AS, was not
impacted by the medium pH. However, following the initial AS permeation, which seems
to have saturated the sublayers of the sublingual membranes, the less ionized AS at higher
pH resulted in higher permeation than the ionized AS at lower pH.
The mean (± SD) of AUC0-90 of AS permeated, J, and P from AS FDSTs (formulation
R1) in a diffusion medium of a pH of 8 were statistically higher (p<0.05) than at all other
pH media (pH 5, 6.5 and 6.8) (Table VIII). The P of AS FDSTs was increased 2-fold at pH
8 compared to pH 6.8, which represented the average saliva pH (Table XII).
According to Lee et al., 2005, they found that for basic drugs with a high pKa, the
permeability through Caco-2 monolayers was increased as the pH increased (Lee et al.,
2005). These results were in agreement with our findings for AS and comply with the pHpartition theory. Therefore, by modifying the microenvironment pH of the saliva to pH 8,
the unionized form of AS would be increased and hence its sublingual absorption will be
increased.
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Table XII. The enhancement in AS permeability coefficient (p) for all AS FDST
formulations compared to control p value (R1 at medium pH 6.8)
AS FDST Formulations
R2

R3

R4

R5

R6

R7

R8

R9

R10

Enhancement in
Permeability
2
2
13
2
6
7
2
1.5
coefficient, P
(fold)
R2: AS FDSTs with Na Bicarb 2%; R3: AS FDSTs with Na Bicarb 2% and SDS 0.5%;
R4: AS FDSTs with Na Bicarb 2% and SDS 1%; R5: AS FDSTs with Na Bicarb 2% and
PCC 16%; R6: AS FDSTs with Na Bicarb 2% and Na Gly 15%; R7: AS FDSTs with Na
Bicarb 2% and Na Gly 20%; R8: AS FDSTs with SDS 1%; R9: AS FDSTs with PCC 16%;
R10: AS FDSTs with Na Gly 20%.

The Effect of Different pH-modifiers on the pH of AS Solution

The addition of pH-modifiers to the tablet formulation to be administered sublingually
ensures that the pH of the saliva is controlled within the range that is optimal for drug
absorption. In order to change the microenvironmental pH of the saliva and sublingual area,
different pH-modifiers were tested in different concentrations to assess their ability to
modify the AS solution pH to pH 8. As per our previous results in section 4.4.2, pH 8 was
found to be the pH at which the cumulative amount of AS permeated, J, and P through the
sublingual membrane were the highest.
Various pH-modifying excipients were tested. All the pH-modifiers used were a nonirritating salts that can be used safely in sublingual area. At a 1% initial concentration, Na
Bicarb, Ca Carb, or Na Cit were able to modify the pH of water. However, this pH
modification was not statistically different (p>0.05) from the pH of the water. By
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increasing the concentration of pH-modifying excipients from 1% to 2%, Na Bicarb was
able to show a significantly higher pH (p<0.05) from water and the rest of pH-modifying
excipients tested (
Table IX). This means that Na Bicarb has the highest potential to modify the
microenvironment of the saliva, however, an appropriate concentration of Na Bicarb had
to be used in order to achieve the desired pH (Badawy & Hussain, 2007).
In order to asses any potential interference for AS or the excipients used in the tablet
formulation on the functionality of Na Bicarb in modifying the pH to the desired optimal
pH, Na Bicarb 2% was tested again with the addition of one AS FDST. The solution’s

Concentration
(%)

pH-Modifiers
Na Bicarb

Ca Carb

Na Cit

1%

7.2 ± 0.2

6.6 ± 0.1

6.2 ±0.3

2%

8.1 ± 0.3*

7.6 ± 0.1

7.5 ± 0.1

7.9 ± 0.1
2% with AS FDSTs
overall pH was measured. Similar pH results were obtained for the solution (

Table IX), which indicated that AS and the excipients used in AS FDSTs formulation had
no negative impact on modifying the pH to pH 8 and they did not interfere with the
intended function for incorporating Na Bicarb in the tablet formulation.

The Effect of incorporating a pH-modifier and/or Penetration Enhancers on the
Physical Characteristics of AS FDST Formulations

In order to evaluate the effect Na Bicarb 2% as a pH-modifier and/or penetration
enhancers on AS SL permeability, these excipients need to be of incorporated into the AS
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FDSTs formulation, However, these changes in the tablet formulation my negatively
impact the tablets’ characteristics.
When direct compression method is used to manufacture tablets, powder flowability
becomes a critical parameter to control for. It can be determined by measuring the angle of
repose and the MC of the powder (Alyami et al., 2017). High MC can result in variable
tablet characteristics and performance. All prepared and tested AS FDST formulations had
good flowability according to the USP (USP/NF, 2018d) (Table VI). However, when only
the transcellular and paracellular enhancers were incorporated in to AS FDST formulations
(formulation R8, R9, R10), the MC was statistically higher (p<0.05) compared to the
previously tested AS FDST formulations with a pH-modifier alone, or with a pH-modifier
and a penetration enhancer (Formulation R2, R3, R4, R5, R6, and R7) (Table VI).
Even though the addition of penetration enhancers had negatively affected the MC of
the powder formulations, these changes did not impact the powder angle of repose and the
tablets’ breaking force. All AS FDST formulations were compressible within similar
compression forces (120 – 140 kgf) and resulted in the formation of hard compact that
passed the friability test with less than 1% weight loss. Therefore, although the
incorporation of pH-modifier and/or penetration enhancers resulted in an increase in the
powder MC, this increase was not significant enough to negatively impact the tablet
characteristics (Table VI).
The different AS FDST formulations that have been prepared were able to pass the AV
of the CU test according to the USP criteria (USP/NF, 2018c) (Table VI). This showed that
incorporating Na Bicarb 2% as a pH-modifier and/or the addition of penetration enhancers
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did not influence the flow and the uniformity of the blend during mixing, which resulted
in a uniform distribution of AS between the AS FDSTs.
The DT can influence the rate and extent of AS sublingual dissolution and absorption.
Testing the DT is very critical for ODT formulations because rapid disintegration is the
key of a successful ODT formulation. Since the USP DT is unable to detect small difference
between different ODT formulations, a disintegration test developed in our lab was used
to evaluate the DT of different AS FDST formulations. This test was designed to take in
consideration the critical key attributes and environment in the sublingual area, including
the small amount of saliva available for tablet disintegrate and static environment under
the tongue (Aodah et al., 2017). Using this DT as described previously, the incorporation
of penetration enhancers into the AS FDSTs formulation containing MCC UF-702, which
found to enhance tablet characteristics and AS sublingual permeability, retarded tablet’s
disintegration and significantly increased its DT (p<0.05) in comparison to formulation R1
and formulations with only Na Bicarb (Table VI). This can be explained mainly by the
reduction in overall table porosity. Previously, It has been demonstrated that highly watersoluble excipients used at high concentrations could absorb and retain the limited available
water to dissolve them, which limits the water from traveling within the tablet through the
capillary channels created by MCC to induce the swelling of the superdisintegrant that
cause tablet’s disintegration. Also, the reduction in MCC content due to the addition of
non-porous and less water-soluble excipients would lower the overall tablet porosity and
therefore would delay tablet disintegration due to reduction in the extent of capillary
pathways within the tablet that water uses to travel through to induce fast disintegration.
However, the incorporation of Na Bicarb along with penetration enhancers improved the
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DT, which can be explained by the high aqueous solubility of Na Bicarb and its low
concentration used. As a result, the dissolution of Na Bicarb created more porous tablet
without limiting water penetration and compensated for the reduction in tablet porosity due
to the incorporation of penetration enhancers on the expense of MCC.
Paracellular enhancers PCC 16% was found to significantly increase (p<0.05) the
disintegration time of AS FDSTs when incorporated to the formulation either with Na
Bicarb 2% or alone compared to all other formulations (Table VI). This mean that Na
Bicarb was not able to reduce the PCC negative effect on tablet characteristics to the same
extent as with SDS and Na Gly.
The results of WT test relies on the results of tablets’ disintegration time. The wetting
time needed for FDSTs is another critical parameter that is more sensitive to FDST
formulations’ differences than DT since it demonstrates the ability of the tablet to withdraw
water into the tablet from the sublingual cavity under extreme conditions like in dry mouth.
The tablet relies on the penetration of saliva by capillary diffusion to allow for tablets’
disintegration and dissolution. In the previously described WT test, the tablet is in
contacted with the wetted tissue from one side only, therefore, water penetrated mainly
from one side of the tablets to the entire tablet. A significant increase in the tablet’s WT
was only observed for AS FDSTs containing SDS or Na Gly without Na Bicarb, and PCC
with and without Na Bicarb, which can be related, as previously explained, to the reduction
in the overall tablet porosity due to the incorporation of penetration enhancers (Table VI).
On the other hand, the addition of the pH-modifier Na Bicarb 2% in the various AS FDSTs
(formulation R3, R4, R6, and R7) did not negatively affect the WT (P<0.05) in comparison
to formulation R1 (Table VI). This can be due to the high solubility of Na Bicarb as
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previously discussed, which did not retard water penetration at the concentration used and
was able to create more porous tablet after its dissolution and balanced out the reduction in
tablet porosity by the incorporation of less water-soluble penetration enhancers.
Water uptake is a test that was used for FDST to assess the tablet’s swelling and its
capacity to absorb and hold water in order to facilitate drug dissolution. The results from
WU test for formulation R1, which contained no pH-modifier and no penetration enhancer,
was significantly higher (p<0.05) than all other formulations (Table VI). The incorporation
of additional excipients on the expense of MCC and L-HPC in the rest of the AS FDST
formulations lowered the ability of the suprdisitegrant, L-HPC, to expand or swell to the
same extent as in formulation R1; and lowered the filler’s ability, MCC, to create a similar
level of tablet porosity as in formulation R1 to accommodate similar amount of absorbed
water within the tablet.
The DD % was measured to determine the amount of the drug released and dissolved
from FDSTs in 1 min. A previously developed method was used to simulate AS FDSTs
dissolution in the oral cavity (Rachid et al., 2011). The addition of a pH-modifier Na Bicarb
2% and penetration enhancers did not negatively impact (p>0.05) the percentage of AS
dissolved in 1 minute (Table VI). However, PCC 16% with or without a pH-modifier
(formulation R5 & R9) had significantly less (p<0.05) drug percentage dissolved in
comparison to the other formulations (Table VI).
In spite of the differences between these AS FDST formulations, all of these tablets
possessed the attributes for a good AS FDST and were within the acceptable and expected
ranges, except for AS FDST with PCC 16% with or without a pH-modifier (formulation
R5 & R9).
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The Effect of Incorporating a pH-modifier and/or Penetration Enhancers on The
Sublingual Permeability of AS FDST Formulations

AS FDSTs were designed to be administered sublingually. Therefore, the processes for
complete drug delivery of the therapeutic dose should not take longer than 1–2 minutes for
the treatment of emergency conditions and for minimizing the swallowing of the tablet or
its components into the GIT. During this time, the tablet should have been disintegrated,
the drug dissolved, and a therapeutic drug amount immediately permeated and absorbed
through the sublingual mucosa. Any remaining amount of the drug after it has been
permeated but not yet necessarily absorbed based on drug permeability coefficient may
accumulates in the submucosal layers of the sublingual membrane and result in further
drug absorption (Wang & Chow, 2014). Excess drug released from the tablet and dissolved
in the sublingual area beyond the sublingual epithelial cells’ absorption capacity, it will not
be absorbed and can be lost into the GIT. This explanation was also adopted in the previous
sublingual animal studies for epinephrine (M. M. Rawas-Qalaji et al., 2006; M. M. RawasQalaji et al., 2015). Tablet’s DT and DD% can be considered the main limiting tablet’s
physical characteristics that can impact AS sublingual permeation, absorption, and relative
bioavailability. Tablet’s DT can control the rate of drug release and indirectly the rate of
drug dissolution (DD%). Therefore, both DT and DD can control the amount of drug
available for absorption, i.e. drug concentration, during the short and limited time of
sublingual administration. According to Fick’s law, altering the initial drug concentration
will alter the rate of diffusion, i.e. drug influx.
Considering the importance of the period right after the sublingual drug administration
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for AS permeation and absorption for the treatment of emergency condition, ex vivo
permeability studies were performed for all AS FDST formulations. In order to understand
and evaluate the mechanism for enhancing drug permeation, the ex vivo permeability
studies for AS FDSTs formulation containing a pH-modifier Na Bicarb 2% alone
(formulation R2), AS FDST formulations containing a pH-modifier Na Bicarb 2% and
penetration enhancers, SDS, PCC, and Na Gly (formulations R3, R4, R5, R6, R7), and AS
FDST formulations with penetration enhancers alone, SDS, PCC, Na Gly (formulations
R8, R9, and R10) were compared to AS FDSTs formulation (R1). The mean (± SD) area
under the curve (AUC0-90) of cumulative drug permeated from AS FDST formulations
containing a pH-modifier with penetration enhancers (formulations R3, R4, R5, R6, and
R7) were statistically higher (p<0.05) than AS FDST formulations containing penetration
enhancers only (formulations R8, R9, and R10), pH-modifier only (formulation R2), and
control (formulation R1) (Table X). Incorporating SDS 1% with Na Bicarb 1%
(formulation R4) achieved the highest enhancement in AS sublingual permeability
(p<0.05) and increased AS permeability 13-fold compared to control (formulation R1)
(Table XII).
Our studies demonstrated that the enhancement in AS sublingual permeability was
correlated with the concentration of penetration enhancers used. The higher the
concentration, the higher the amount of drug permeated. However, the maximum allowed
concentrations to be used in AS FDST formulations were limited to their safety profile.
Also, the results from our studies indicated that the addition of transcellular penetration
enhancers with a pH-modifier had a synergistic effect on AS sublingual permeability.

The mean (± SD) AUC0-90
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and J from AS FDSTs with transcellular enhancers alone,

SDS and Na Gly (formulation R8 and R10) were significantly higher (p<0.05) than with
paracellular enhancer PCC (formulation R9) (Table XI). However, the mean (± SD) AS P
from AS FDSTs with SDS transcellular enhancers were significantly higher (p<0.05) than
AS FDSTs with Na Gly transcellular enhancers, PCC paracellular enhancer, and control.
These findings demonstrated that AS follow the transcellular transport pathway for its
sublingual absorption.
The amount of AS permeated from AS FDSTs formulation with paracellular enhancer
PCC (formulation R9) increased at 75 min compared to AS FDSTs with transcellular
enhancers, SDS and Na Gly (formulation R8 and R10). The reason for this increasement
was due to the accumulation of AS in the donor cell to the extent that was able to overcome
the permeability resistance in the sublingual membrane. This is probably irrelevant to
emergency treatment situations, especially during the short sublingual administration time.
Also, our previous dose escalating ex vivo permeability studies using formulation B
showed that increasing AS dose resulted in a linear increase of AS permeability (Aodah et
al., 2017). These results are an indication for a passive sublingual AS transport mechanism.
Therefore, It can be concluded that AS transport is mainly by passive transcellular transport
pathway, which is in agreement with previously suggested transport mechanism.
These studies confirmed the potential and the benefits of modulating the absorption’s
microenvironment pH, to reduce AS ionization, as a promising approach for enhancing AS
permeation through sublingual epithelial cells. This enhancement can be further increased
by the addition of a transcellular penetration enhancer.
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Recommendations for Future Studies

In the interests of developing AS FDSTs as a new dosage form to treat the emergency
condition of OP toxicity, future in vivo pharmacokinetics animal studies are recommended.
In vivo animal studies will evaluate and confirm the effect of changing the
microenvironment pH on drug ionization as well as the effect of penetration enhancers on
enhancing AS sublingual permeability. A does-escalating animal studies are recommended
to determine the sublingual AS dose bioequivalent to AtroPen®. These preclinical animal
studies will guide the dose selection for any future clinical studies.
It is known that improving or masking the bad taste of drugs intended for oral
administration can improve patient compliance. Atropine sulfate is known for its bitter
taste when administered orally (Maggs, 2008). Therefore, various taste masking
approaches for AS FDSTs are recommended to mask the bitter taste of AS before
conducting human studies.

Conclusion

In this project, different AS FDST formulations were successfully manufactured and
evaluated. The quality control methods used in this project were able to successfully
discriminate and detect formulations differences. The newer highly compressible MCC
filler grade UF-702 was able to successfully alter the properties of AS FDSTs and improve
the AS dissolution rate, and therefore, the rate and extent of AS sublingual permeation.
Reducing AS ionization through altering the diffusion medium’s pH by incorporating an
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appropriate pH-modifier into the AS FDSTs formulation can be a useful approach to
enhance AS sublingual permeation. This approach enhanced AS sublingual permeability
2-fold compared to the control (Table XII).
Combining a transcellular penetration enhancer along with a pH-modifier into the AS
FDST formulations, enhanced AS sublingual permeation between 7 to 13-fold (Table XII).
This study, therefore, innovatively improved the permeability of sublingually administered
AS FDSTs through altering the medium pH and the addition of penetration enhancers.
This novel AS FDSTs are expected to significantly improve the pharmacokinetic
parameters (AUC, Cmax, and Tmax) in future animal studies and reduce the bioequivalent
sublingual AS dose. The successful development of these novel AS FDSTs as alternative
dosage form for AtroPen® will ensure the sublingual delivery of therapeutic AS
concentrations to the systemic circulation and the rapid onset of action for the treatment of
OP toxicity as a first-aid treatment until patients are transported to appropriate health
facility. This new dosage form will offer an affordable, easy-to-administer, non-invasive,
and portable alternative dosage form for the treatment OP toxicities.
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